1 | G-CSF | 1件: Filgrastim Filgrastim | 1件: D03235
D03235
| 1件: CSF3R CSF3R 💬 | 5件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Hematopoietic cell lineage, JAK-STAT signaling pathway, PI3K-Akt signaling pathway, Pathways in cancer 💬 | 16件: 2 2, 6, 11, 13, 16, 47, 49, 51, 60, 62, 65, 85, 96, 284, 285, 331 |
2 | G-CSF for Conditioning before HSCT. | 1件: Filgrastim Filgrastim | 1件: D03235
D03235
| 1件: CSF3R CSF3R 💬 | 5件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Hematopoietic cell lineage, JAK-STAT signaling pathway, PI3K-Akt signaling pathway, Pathways in cancer 💬 | 1件: 65 65 |
3 | G02CB03 | - | - | - | - | 1件: 75 75 |
4 | G048E03 | - | - | - | - | 1件: 85 85 |
5 | G04BE03 | - | - | - | - | 1件: 86 86 |
6 | G04BE03- Sildenafil - sildenafil (citrato) | 1件: Sildenafil Sildenafil | 2件: D02229
D02229
,
D08514
| 1件: PDE5A PDE5A 💬 | 3件: Metabolic pathways Metabolic pathways, Purine metabolism, cGMP-PKG signaling pathway 💬 | 1件: 86 86 |
7 | G04BE08 | - | - | - | - | 1件: 86 86 |
8 | G04CB02 | - | - | - | - | 1件: 2 2 |
9 | G1117337 | - | - | - | - | 2件: 67 67, 299 |
10 | G1567970 | - | - | - | - | 3件: 46 46, 53, 97 |
11 | G1XCG | - | - | - | - | 1件: 65 65 |
12 | G1XCGD transduced CD34+ cells | - | - | - | - | 1件: 65 65 |
13 | G2-SFM (IFN-beta-1a from clone 484-39,FBS-free process) | - | - | - | - | 1件: 13 13 |
14 | G321605 | - | - | - | - | 3件: 85 85, 96, 97 |
15 | G451990 | - | - | - | - | 2件: 51 51, 85 |
16 | G914167 | - | - | - | - | 1件: 299 299 |
17 | G957389 | - | - | - | - | 1件: 299 299 |
18 | GA | - | - | - | - | 1件: 13 13 |
19 | GA 20 mg/mL | - | - | - | - | 1件: 13 13 |
20 | GA 40 mg/mL | - | - | - | - | 1件: 13 13 |
21 | GA Depot | - | - | - | - | 1件: 13 13 |
22 | GA Depot 25mg once monthly | - | - | - | - | 1件: 13 13 |
23 | GA Depot 40 mg | - | - | - | - | 1件: 13 13 |
24 | GA Depot 40mg once monthly | - | - | - | - | 1件: 13 13 |
25 | GA Depot 80 mg | - | - | - | - | 1件: 13 13 |
26 | Ga-68-DOTA-NOC | - | - | - | - | 1件: 84 84 |
27 | GA-GCB | 1件: Velaglucerase alfa Velaglucerase alfa | 1件: D09029
D09029
| 1件: GBA GBA 💬 | 4件: Lysosome Lysosome, Metabolic pathways, Other glycan degradation, Sphingolipid metabolism 💬 | 1件: 19 19 |
28 | GA-GCB (velaglucerase alfa) | 1件: Velaglucerase alfa Velaglucerase alfa | 1件: D09029
D09029
| 1件: GBA GBA 💬 | 4件: Lysosome Lysosome, Metabolic pathways, Other glycan degradation, Sphingolipid metabolism 💬 | 1件: 19 19 |
29 | GABAPENTIN | 1件: Gabapentin Gabapentin | 1件: D00332
D00332
| 5件: CACNA2D1 CACNA2D1, CACNA2D2, CACNA2D3, CACNA2D4, SLC6A1 💬 | 9件: Adrenergic signaling in cardiomyocytes Adrenergic signaling in cardiomyocytes, Arrhythmogenic right ventricular cardiomyopathy, Cardiac muscle contraction, Dilated cardiomyopathy, GABAergic synapse, Hypertrophic cardiomyopathy, MAPK signaling pathway, Oxytocin signaling pathway, Synaptic vesicle cycle 💬 | 5件: 6 6, 13, 19, 70, 298 |
30 | Gabapentin prescriptions | 1件: Gabapentin Gabapentin | 1件: D00332
D00332
| 5件: CACNA2D1 CACNA2D1, CACNA2D2, CACNA2D3, CACNA2D4, SLC6A1 💬 | 9件: Adrenergic signaling in cardiomyocytes Adrenergic signaling in cardiomyocytes, Arrhythmogenic right ventricular cardiomyopathy, Cardiac muscle contraction, Dilated cardiomyopathy, GABAergic synapse, Hypertrophic cardiomyopathy, MAPK signaling pathway, Oxytocin signaling pathway, Synaptic vesicle cycle 💬 | 1件: 298 298 |
31 | GABAPENTINA | 1件: Gabapentin Gabapentin | 1件: D00332
D00332
| 5件: CACNA2D1 CACNA2D1, CACNA2D2, CACNA2D3, CACNA2D4, SLC6A1 💬 | 9件: Adrenergic signaling in cardiomyocytes Adrenergic signaling in cardiomyocytes, Arrhythmogenic right ventricular cardiomyopathy, Cardiac muscle contraction, Dilated cardiomyopathy, GABAergic synapse, Hypertrophic cardiomyopathy, MAPK signaling pathway, Oxytocin signaling pathway, Synaptic vesicle cycle 💬 | 1件: 6 6 |
32 | GABAPENTINA KERN PHARMA | 1件: Gabapentin Gabapentin | 1件: D00332
D00332
| 5件: CACNA2D1 CACNA2D1, CACNA2D2, CACNA2D3, CACNA2D4, SLC6A1 💬 | 9件: Adrenergic signaling in cardiomyocytes Adrenergic signaling in cardiomyocytes, Arrhythmogenic right ventricular cardiomyopathy, Cardiac muscle contraction, Dilated cardiomyopathy, GABAergic synapse, Hypertrophic cardiomyopathy, MAPK signaling pathway, Oxytocin signaling pathway, Synaptic vesicle cycle 💬 | 1件: 6 6 |
33 | Gabapentine | 1件: Gabapentin Gabapentin | 1件: D00332
D00332
| 5件: CACNA2D1 CACNA2D1, CACNA2D2, CACNA2D3, CACNA2D4, SLC6A1 💬 | 9件: Adrenergic signaling in cardiomyocytes Adrenergic signaling in cardiomyocytes, Arrhythmogenic right ventricular cardiomyopathy, Cardiac muscle contraction, Dilated cardiomyopathy, GABAergic synapse, Hypertrophic cardiomyopathy, MAPK signaling pathway, Oxytocin signaling pathway, Synaptic vesicle cycle 💬 | 1件: 13 13 |
34 | Gabapentine 300mg | 1件: Gabapentin Gabapentin | 1件: D00332
D00332
| 5件: CACNA2D1 CACNA2D1, CACNA2D2, CACNA2D3, CACNA2D4, SLC6A1 💬 | 9件: Adrenergic signaling in cardiomyocytes Adrenergic signaling in cardiomyocytes, Arrhythmogenic right ventricular cardiomyopathy, Cardiac muscle contraction, Dilated cardiomyopathy, GABAergic synapse, Hypertrophic cardiomyopathy, MAPK signaling pathway, Oxytocin signaling pathway, Synaptic vesicle cycle 💬 | 1件: 13 13 |
35 | Gaboxadol | 1件: Gaboxadol Gaboxadol | 1件: D04282
D04282
| 16件: GABRA1 GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ 💬 | 7件: GABAergic synapse GABAergic synapse, Morphine addiction, Neuroactive ligand-receptor interaction, Nicotine addiction, Retrograde endocannabinoid signaling, Serotonergic synapse, Taste transduction 💬 | 2件: 201 201, 206 |
36 | GABOXADOL MONOHYDRATE | 1件: Gaboxadol Gaboxadol | 1件: D04282
D04282
| 16件: GABRA1 GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ 💬 | 7件: GABAergic synapse GABAergic synapse, Morphine addiction, Neuroactive ligand-receptor interaction, Nicotine addiction, Retrograde endocannabinoid signaling, Serotonergic synapse, Taste transduction 💬 | 1件: 201 201 |
37 | Gaboxadol monohydrate 0.5 mg | 1件: Gaboxadol Gaboxadol | 1件: D04282
D04282
| 16件: GABRA1 GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ 💬 | 7件: GABAergic synapse GABAergic synapse, Morphine addiction, Neuroactive ligand-receptor interaction, Nicotine addiction, Retrograde endocannabinoid signaling, Serotonergic synapse, Taste transduction 💬 | 1件: 201 201 |
38 | Gaboxadol monohydrate 0.5 mg (intended commercial formulation) | 1件: Gaboxadol Gaboxadol | 1件: D04282
D04282
| 16件: GABRA1 GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ 💬 | 7件: GABAergic synapse GABAergic synapse, Morphine addiction, Neuroactive ligand-receptor interaction, Nicotine addiction, Retrograde endocannabinoid signaling, Serotonergic synapse, Taste transduction 💬 | 1件: 201 201 |
39 | Gaboxadol monohydrate 0.5 mg capsule | 1件: Gaboxadol Gaboxadol | 1件: D04282
D04282
| 16件: GABRA1 GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ 💬 | 7件: GABAergic synapse GABAergic synapse, Morphine addiction, Neuroactive ligand-receptor interaction, Nicotine addiction, Retrograde endocannabinoid signaling, Serotonergic synapse, Taste transduction 💬 | 1件: 201 201 |
40 | Gaboxadol monohydrate 2 mg | 1件: Gaboxadol Gaboxadol | 1件: D04282
D04282
| 16件: GABRA1 GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ 💬 | 7件: GABAergic synapse GABAergic synapse, Morphine addiction, Neuroactive ligand-receptor interaction, Nicotine addiction, Retrograde endocannabinoid signaling, Serotonergic synapse, Taste transduction 💬 | 1件: 201 201 |
41 | Gaboxadol monohydrate 2 mg (intended commercial formulation) | 1件: Gaboxadol Gaboxadol | 1件: D04282
D04282
| 16件: GABRA1 GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ 💬 | 7件: GABAergic synapse GABAergic synapse, Morphine addiction, Neuroactive ligand-receptor interaction, Nicotine addiction, Retrograde endocannabinoid signaling, Serotonergic synapse, Taste transduction 💬 | 1件: 201 201 |
42 | Gaboxadol monohydrate 2 mg capsule | 1件: Gaboxadol Gaboxadol | 1件: D04282
D04282
| 16件: GABRA1 GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ 💬 | 7件: GABAergic synapse GABAergic synapse, Morphine addiction, Neuroactive ligand-receptor interaction, Nicotine addiction, Retrograde endocannabinoid signaling, Serotonergic synapse, Taste transduction 💬 | 1件: 201 201 |
43 | Gaboxadol monohydrate 5 mg | 1件: Gaboxadol Gaboxadol | 1件: D04282
D04282
| 16件: GABRA1 GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ 💬 | 7件: GABAergic synapse GABAergic synapse, Morphine addiction, Neuroactive ligand-receptor interaction, Nicotine addiction, Retrograde endocannabinoid signaling, Serotonergic synapse, Taste transduction 💬 | 1件: 201 201 |
44 | Gaboxadol monohydrate 5 mg (intended commercial formulation) | 1件: Gaboxadol Gaboxadol | 1件: D04282
D04282
| 16件: GABRA1 GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ 💬 | 7件: GABAergic synapse GABAergic synapse, Morphine addiction, Neuroactive ligand-receptor interaction, Nicotine addiction, Retrograde endocannabinoid signaling, Serotonergic synapse, Taste transduction 💬 | 1件: 201 201 |
45 | Gadobenate | 1件: Gadobenic acid Gadobenic acid | 2件: D04283
D04283
,
D08018
| - | - | 1件: 13 13 |
46 | Gadobenate Dimeglumine | 1件: Gadobenic acid Gadobenic acid | 2件: D04283
D04283
,
D08018
| - | - | 1件: 13 13 |
47 | GADOBUTROL | 1件: Gadobutrol Gadobutrol | 1件: D07420
D07420
| - | - | 3件: 13 13, 22, 46 |
48 | Gadodiamide | 1件: Gadodiamide Gadodiamide | 2件: D01645
D01645
,
D04284
| - | - | 1件: 305 305 |
49 | Gadolinium | 1件: Gadolinium Gadolinium | - | - | - | 6件: 13 13, 34, 46, 58, 65, 86 |
50 | Gadolinium contrast | 1件: Gadolinium Gadolinium | - | - | - | 1件: 34 34 |
51 | Gadolinium For abdomen | 1件: Gadolinium Gadolinium | - | - | - | 1件: 65 65 |
52 | Gadolinium For lower back | 1件: Gadolinium Gadolinium | - | - | - | 1件: 65 65 |
53 | Gadolinium-based contrast | 1件: Gadolinium Gadolinium | - | - | - | 1件: 13 13 |
54 | Gadopentetate | 1件: Gadopentetic acid Gadopentetic acid | 2件: D01707
D01707
,
D08006
| - | - | 2件: 13 13, 34 |
55 | Gadoterate | 1件: Gadoteric acid Gadoteric acid | 1件: D08007
D08007
| - | - | 1件: 53 53 |
56 | Gadoteric acid | 1件: Gadoteric acid Gadoteric acid | 1件: D08007
D08007
| - | - | 1件: 13 13 |
57 | Gadoteridol | 1件: Gadoteridol Gadoteridol | 1件: D01137
D01137
| - | - | 1件: 13 13 |
58 | Gadovist | - | - | - | - | 2件: 13 13, 22 |
59 | GADOVIST 1 mmol/ml solución inyectable en jeringa precargada/ cartucho precargado | - | - | - | - | 1件: 13 13 |
60 | Gadovist 1.0 mmol/ml Injektionslösung | - | - | - | - | 1件: 13 13 |
61 | Galactose | 1件: Galactose Galactose | 1件: D04291
D04291
| - | - | 2件: 171 171, 222 |
62 | Galafold | 1件: Migalastat Migalastat | 1件: D10359
D10359
| - | - | 1件: 19 19 |
63 | GALANTAMINE | 1件: Galantamine Galantamine | 2件: D02173
D02173
,
D04292
| 1件: ACHE ACHE 💬 | 2件: Cholinergic synapse Cholinergic synapse, Glycerophospholipid metabolism 💬 | 2件: 6 6, 127 |
64 | Galantamine hydrobromide | 1件: Galantamine Galantamine | 2件: D02173
D02173
,
D04292
| 1件: ACHE ACHE 💬 | 2件: Cholinergic synapse Cholinergic synapse, Glycerophospholipid metabolism 💬 | 2件: 6 6, 127 |
65 | GALEN® tablet | - | - | - | - | 2件: 43 43, 44 |
66 | GALICAFTOR | 1件: Galicaftor Galicaftor | 1件: D11724
D11724
| 1件: CFTR CFTR 💬 | 8件: ABC transporters ABC transporters, AMPK signaling pathway, Bile secretion, Gastric acid secretion, Pancreatic secretion, Tight junction, Vibrio cholerae infection, cAMP signaling pathway 💬 | 1件: 299 299 |
67 | Gallium nitrate | 2件: Gallium nitrate Gallium nitrate, Nitrate | 2件: D00940
D00940
,
D02313
| - | - | 1件: 299 299 |
68 | Gallium-68 DOTATATE | 1件: Dotatate Dotatate | - | - | - | 1件: 84 84 |
69 | Gallium-68-DOTA-N-Octreotide | 1件: Octreotide Octreotide | 2件: D00442
D00442
,
D06495
| 1件: SSTR2 SSTR2 💬 | 4件: Gastric acid secretion Gastric acid secretion, Growth hormone synthesis, secretion and action, Neuroactive ligand-receptor interaction, cAMP signaling pathway 💬 | 1件: 84 84 |
70 | Gallium68-Dota-Noc | - | - | - | - | 1件: 85 85 |
71 | GALSULFASE | 1件: Galsulfase Galsulfase | 1件: D06565
D06565
| 1件: ARSB ARSB 💬 | 3件: Glycosaminoglycan degradation Glycosaminoglycan degradation, Lysosome, Metabolic pathways 💬 | 1件: 19 19 |
72 | Gamma Globulin | - | - | - | - | 2件: 15 15, 50 |
73 | Gamma interferon | - | - | - | - | 1件: 18 18 |
74 | Gamma-Linolenic acid | 2件: Gamolenic acid Gamolenic acid, alpha-Linolenic acid | 1件: D07213
D07213
| - | - | 1件: 46 46 |
75 | Gamma-secretase/Notch signalling pathway inhibitor RO4929097 | - | - | - | - | 1件: 74 74 |
76 | Gamma-Tocopherol | 2件: Tocopherol Tocopherol, gamma-Tocopherol | 1件: D02332
D02332
| - | - | 1件: 13 13 |
77 | GAMMAGARD LIQUID | - | - | - | - | 1件: 65 65 |
78 | Gammagard S/D (Solvent/Detergent) | - | - | - | - | 1件: 65 65 |
79 | Gammaglobulin | - | - | - | - | 1件: 65 65 |
80 | Gammanorm | - | - | - | - | 2件: 14 14, 65 |
81 | Gammanorm 165 mg/mL | - | - | - | - | 1件: 65 65 |
82 | Gammaplex | - | - | - | - | 2件: 63 63, 65 |
83 | Gammaplex (5%) | - | - | - | - | 1件: 65 65 |
84 | Gammaplex (Intravenous immunoglobulin) | - | - | - | - | 1件: 65 65 |
85 | Gammaplex 10 | 1件: Human immunoglobulin G Human immunoglobulin G | - | - | - | 1件: 65 65 |
86 | Gammaplex, intravenous immunoglobulin | - | - | - | - | 1件: 63 63 |
87 | GAMUNEX 10% | 1件: Human immunoglobulin G Human immunoglobulin G | - | - | - | 1件: 11 11 |
88 | GAMUNEX-C | - | - | - | - | 1件: 65 65 |
89 | Ganaxolone | 1件: Ganaxolone Ganaxolone | 1件: D04300
D04300
| 16件: GABRA1 GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ 💬 | 7件: GABAergic synapse GABAergic synapse, Morphine addiction, Neuroactive ligand-receptor interaction, Nicotine addiction, Retrograde endocannabinoid signaling, Serotonergic synapse, Taste transduction 💬 | 4件: 145 145, 152, 158, 206 |
90 | Ganaxolone, SPT3162, MD 9150000, CCD-1042, Mepalon 1042, (3a-hydroxy-3beta-methyl-5a-pregnan-20-one) | 1件: Ganaxolone Ganaxolone | 1件: D04300
D04300
| 16件: GABRA1 GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ 💬 | 7件: GABAergic synapse GABAergic synapse, Morphine addiction, Neuroactive ligand-receptor interaction, Nicotine addiction, Retrograde endocannabinoid signaling, Serotonergic synapse, Taste transduction 💬 | 1件: 152 152 |
91 | Ganaxolone, SPT3162, MD 9150000, CCD-1042, Mepalon 1042, (3a-hydroxy-3ß-methyl-5a-pregnan-20-one) | 1件: Ganaxolone Ganaxolone | 1件: D04300
D04300
| 16件: GABRA1 GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ 💬 | 7件: GABAergic synapse GABAergic synapse, Morphine addiction, Neuroactive ligand-receptor interaction, Nicotine addiction, Retrograde endocannabinoid signaling, Serotonergic synapse, Taste transduction 💬 | 1件: 152 152 |
92 | Ganciclovir | 1件: Ganciclovir Ganciclovir | 2件: D00333
D00333
,
D04301
| - | - | 3件: 28 28, 60, 97 |
93 | Ganoderma | - | - | - | - | 1件: 6 6 |
94 | Gardasil | 1件: Human papillomavirus type 6 L1 capsid protein antigen Human papillomavirus type 6 L1 capsid protein antigen | - | - | - | 1件: 49 49 |
95 | Garetosmab | 1件: Garetosmab Garetosmab | 1件: D11443
D11443
| - | - | 1件: 272 272 |
96 | Garlic | 1件: Garlic Garlic | 1件: D12020
D12020
| - | - | 1件: 299 299 |
97 | Gastro-resistant phosphatidylcholine granules | 1件: Lecithin Lecithin | 1件: D04682
D04682
| - | - | 1件: 97 97 |
98 | Gastrointestinal evaluation | - | - | - | - | 1件: 78 78 |
99 | Gastroscopy | - | - | - | - | 1件: 97 97 |
100 | Gastrus | - | - | - | - | 1件: 66 66 |
101 | Gazyvaro | 1件: Obinutuzumab Obinutuzumab | 1件: D09321
D09321
| 1件: MS4A1 MS4A1 💬 | 1件: Hematopoietic cell lineage Hematopoietic cell lineage 💬 | 2件: 49 49, 222 |
102 | GAZYVARO - 1000 MG - CONCENTRATO PER SOLUZIONE PER INFUSIONE - USO ENDOVENOSO - FLACONCINO - 1000MG/40ML - 1 FLACONCINO | 1件: Obinutuzumab Obinutuzumab | 1件: D09321
D09321
| 1件: MS4A1 MS4A1 💬 | 1件: Hematopoietic cell lineage Hematopoietic cell lineage 💬 | 1件: 222 222 |
103 | GB-0998 | - | - | - | - | 1件: 50 50 |
104 | GB-0998 (Intravenous immunoglobulin) | - | - | - | - | 1件: 11 11 |
105 | GB002 | - | - | - | - | 1件: 86 86 |
106 | GB002 (seralutinib) | - | - | - | - | 1件: 86 86 |
107 | GB002 Capsules | - | - | - | - | 1件: 86 86 |
108 | GB004 | - | - | - | - | 1件: 97 97 |
109 | GB004-HCl | - | - | - | - | 1件: 97 97 |
110 | GB0139 | - | - | - | - | 1件: 85 85 |
111 | GB0139 (previously known as TD139) | - | - | - | - | 1件: 85 85 |
112 | GB224 10mg | - | - | - | - | 1件: 46 46 |
113 | GB224 15mg | - | - | - | - | 1件: 46 46 |
114 | GB224 20mg | - | - | - | - | 1件: 46 46 |
115 | GB224 2mg | - | - | - | - | 1件: 46 46 |
116 | GB224 30mg | - | - | - | - | 1件: 46 46 |
117 | GB224 5mg | - | - | - | - | 1件: 46 46 |
118 | GB242 | - | - | - | - | 1件: 46 46 |
119 | GBP | - | - | - | - | 1件: 13 13 |
120 | GBT440 | - | - | - | - | 1件: 85 85 |
121 | GBT440 300 mg capsule | - | - | - | - | 1件: 85 85 |
122 | GBT440 300 mg tablet | - | - | - | - | 1件: 85 85 |
123 | GC+HCQ | - | - | - | - | 1件: 49 49 |
124 | GC1008 | 1件: Fresolimumab Fresolimumab | 1件: D09620
D09620
| 3件: TGFB1 TGFB1, TGFB2, TGFB3 💬 | 35件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Amoebiasis, Cell cycle, Cellular senescence, Chagas disease, Chronic myeloid leukemia, Colorectal cancer, Cytokine-cytokine receptor interaction, Diabetic cardiomyopathy, Dilated cardiomyopathy, FoxO signaling pathway, Gastric cancer, Hepatitis B, Hepatocellular carcinoma, Hippo signaling pathway, Human T-cell leukemia virus 1 infection, Hypertrophic cardiomyopathy, Inflammatory bowel disease, Intestinal immune network for IgA production, Leishmaniasis, MAPK signaling pathway, Malaria, MicroRNAs in cancer, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pancreatic cancer, Pathways in cancer, Proteoglycans in cancer, Relaxin signaling pathway, Renal cell carcinoma, Rheumatoid arthritis, TGF-beta signaling pathway, Th17 cell differentiation, Toxoplasmosis, Tuberculosis 💬 | 2件: 85 85, 222 |
125 | GC1111_0.5mg/kg | - | - | - | - | 1件: 19 19 |
126 | GC1111_1.0mg/kg | - | - | - | - | 1件: 19 19 |
127 | GC1119 | - | - | - | - | 1件: 19 19 |
128 | GCK 100 mg | - | - | - | - | 1件: 46 46 |
129 | GCK 200 mg | - | - | - | - | 1件: 46 46 |
130 | GCK 300 mg | - | - | - | - | 1件: 46 46 |
131 | Gcsf | - | - | - | - | 1件: 65 65 |
132 | GDC-0134 | - | - | - | - | 1件: 2 2 |
133 | GDC-0853 | - | - | - | - | 3件: 13 13, 46, 49 |
134 | GDC-0853 RO7010939 | - | - | - | - | 3件: 13 13, 46, 49 |
135 | GDNF & Synchro Med Infusion System | - | - | - | - | 1件: 5 5 |
136 | GE180 PET Scan | - | - | - | - | 1件: 6 6 |
137 | GED-0301 | - | - | - | - | 2件: 96 96, 97 |
138 | GED-0507-34-LEVO | 1件: GED-0507-34-Levo GED-0507-34-Levo | - | - | - | 1件: 97 97 |
139 | GED-0507-34-Levo 160 mg | 1件: GED-0507-34-Levo GED-0507-34-Levo | - | - | - | 1件: 97 97 |
140 | GED-0507-34-Levo 80 mg | 1件: GED-0507-34-Levo GED-0507-34-Levo | - | - | - | 1件: 97 97 |
141 | GED0507 | - | - | - | - | 1件: 97 97 |
142 | Gefapixant | 1件: Gefapixant Gefapixant | 1件: D11349
D11349
| 1件: P2RX3 P2RX3 💬 | 3件: Calcium signaling pathway Calcium signaling pathway, Neuroactive ligand-receptor interaction, Taste transduction 💬 | 2件: 85 85, 226 |
143 | Gefitinib | 1件: Gefitinib Gefitinib | 1件: D01977
D01977
| 1件: EGFR EGFR 💬 | 48件: Adherens junction Adherens junction, Bladder cancer, Breast cancer, Calcium signaling pathway, Central carbon metabolism in cancer, Chemical carcinogenesis - reactive oxygen species, Chemical carcinogenesis - receptor activation, Choline metabolism in cancer, Colorectal cancer, Coronavirus disease - COVID-19, Cushing syndrome, EGFR tyrosine kinase inhibitor resistance, Endocrine resistance, Endocytosis, Endometrial cancer, Epithelial cell signaling in Helicobacter pylori infection, ErbB signaling pathway, Estrogen signaling pathway, Focal adhesion, FoxO signaling pathway, Gap junction, Gastric cancer, Glioma, GnRH signaling pathway, HIF-1 signaling pathway, Hepatitis C, Hepatocellular carcinoma, Human cytomegalovirus infection, Human papillomavirus infection, JAK-STAT signaling pathway, MAPK signaling pathway, Melanoma, MicroRNAs in cancer, Non-small cell lung cancer, Oxytocin signaling pathway, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Parathyroid hormone synthesis, secretion and action, Pathways in cancer, Phospholipase D signaling pathway, Prostate cancer, Proteoglycans in cancer, Rap1 signaling pathway, Ras signaling pathway, Regulation of actin cytoskeleton, Relaxin signaling pathway, Shigellosis 💬 | 1件: 75 75 |
144 | Gelatin | 1件: Gelatin Gelatin | 2件: D00115
D00115
,
D06892
| - | - | 5件: 28 28, 62, 78, 97, 269 |
145 | Gelatine | 1件: Gelatin Gelatin | 2件: D00115
D00115
,
D06892
| - | - | 1件: 19 19 |
146 | Geleli | - | - | - | - | 1件: 46 46 |
147 | Gemcabene | 1件: Gemcabene Gemcabene | - | - | - | 2件: 79 79, 265 |
148 | Genakumab | - | - | - | - | 1件: 107 107 |
149 | Gene Activated a-Galactosidase A | - | - | - | - | 1件: 19 19 |
150 | Gene Activated Human Glucocerebrosidase | - | - | - | - | 1件: 19 19 |
151 | Gene activated human glucocerebrosidase, velaglucerase alfa | 1件: Velaglucerase alfa Velaglucerase alfa | 1件: D09029
D09029
| 1件: GBA GBA 💬 | 4件: Lysosome Lysosome, Metabolic pathways, Other glycan degradation, Sphingolipid metabolism 💬 | 1件: 19 19 |
152 | Gene Therapy Method for CGD | - | - | - | - | 1件: 65 65 |
153 | Gene Therapy Product-vMCO-010 | - | - | - | - | 1件: 90 90 |
154 | Gene Therapy product:vMCO-I | - | - | - | - | 1件: 90 90 |
155 | Gene transfer | - | - | - | - | 1件: 65 65 |
156 | Gene-Activated Human Glucocerebrosidase | - | - | - | - | 1件: 19 19 |
157 | Gene-Activated Human Glucocerebrosidase 200U/vial | - | - | - | - | 1件: 19 19 |
158 | Gene-Activated Human Glucocerebrosidase 400U/vial | - | - | - | - | 1件: 19 19 |
159 | Gene-modified autologous fibroblasts | - | - | - | - | 1件: 36 36 |
160 | Gene-Transduced Autologous CD34+ Stem Cells | - | - | - | - | 1件: 65 65 |
161 | General anesthesia with tourniquet | - | - | - | - | 1件: 46 46 |
162 | General anesthesia without tourniquet | - | - | - | - | 1件: 46 46 |
163 | General Corticotherapy | - | - | - | - | 1件: 35 35 |
164 | Generic Dry Powder Inhaler | - | - | - | - | 1件: 86 86 |
165 | Generic Syringe then Chrono Super PID-Gammanorm | - | - | - | - | 1件: 65 65 |
166 | Genetic HMI-203 | - | - | - | - | 1件: 19 19 |
167 | Genetic: AAV5-RPGR | - | - | - | - | 1件: 90 90 |
168 | Genetic: AAV5-RPGR 2e11 | - | - | - | - | 1件: 90 90 |
169 | Genetic: AAV5-RPGR 4e11 | - | - | - | - | 1件: 90 90 |
170 | Genetic: Amplification by PCR and direct sequencing on the entire coding sequence and intron-exons boundaries of the candidate gene | - | - | - | - | 1件: 265 265 |
171 | Genetic: Blood draw for optional genetic exome sequencing | - | - | - | - | 3件: 3 3, 15, 256 |
172 | Genetic: Blood or Saliva Sample Collection | - | - | - | - | 1件: 299 299 |
173 | Genetic: CL20-i4-EF1a-h?c-OPT | - | - | - | - | 1件: 65 65 |
174 | Genetic: DNA analysis | - | - | - | - | 2件: 28 28, 60 |
175 | Genetic: DNA bio-banking | - | - | - | - | 1件: 122 122 |
176 | Genetic: FCX-013 | - | - | - | - | 1件: 51 51 |
177 | Genetic: genetic analysis | - | - | - | - | 1件: 96 96 |
178 | Genetic: Genetic test: ACE polymorphism | - | - | - | - | 3件: 3 3, 15, 256 |
179 | Genetic: Genetic test: ACTN3 polymorphism | - | - | - | - | 3件: 3 3, 15, 256 |
180 | Genetic: GLA gene | - | - | - | - | 1件: 19 19 |
181 | Genetic: GS010 | - | - | - | - | 1件: 302 302 |
182 | Genetic: Infusion of autologous cryopreserved EFS-ADA LV CD34+ cells (OTL-101) | - | - | - | - | 1件: 65 65 |
183 | Genetic: Infusion of autologous EFS-ADA LV CD34+ (OTL-101) | - | - | - | - | 1件: 65 65 |
184 | Genetic: Infusion of autologous EFS-ADA LV CD34+ cells | - | - | - | - | 1件: 65 65 |
185 | Genetic: LYS-GM101 | - | - | - | - | 1件: 19 19 |
186 | Genetic: Mesenchymal stromal cells | 1件: Human Umbilical Cord Mesenchymal Stem Cells Human Umbilical Cord Mesenchymal Stem Cells | - | - | - | 1件: 60 60 |
187 | Genetic: microarray analysis | - | - | - | - | 1件: 28 28 |
188 | Genetic: Nicotine dependence | 1件: Nicotine Nicotine | 3件: D03365
D03365
,
D05156
,
D05157
| 16件: CHRNA1 CHRNA1, CHRNA10, CHRNA2, CHRNA3, CHRNA4, CHRNA5, CHRNA6, CHRNA7, CHRNA9, CHRNB1, CHRNB2, CHRNB3, CHRNB4, CHRND, CHRNE, CHRNG 💬 | 7件: Alzheimer disease Alzheimer disease, Calcium signaling pathway, Chemical carcinogenesis - receptor activation, Cholinergic synapse, Neuroactive ligand-receptor interaction, Nicotine addiction, Pathways of neurodegeneration - multiple diseases 💬 | 1件: 13 13 |
189 | Genetic: Optional pharmacogenetic assessment | - | - | - | - | 1件: 6 6 |
190 | Genetic: Ornithine transcarbamylase vector | 1件: Ornithine Ornithine | 1件: D08302
D08302
| - | - | 1件: 251 251 |
191 | Genetic: polymerase chain reaction | - | - | - | - | 2件: 28 28, 60 |
192 | Genetic: Polymorphism Analysis | - | - | - | - | 2件: 49 49, 60 |
193 | Genetic: protein expression analysis | - | - | - | - | 2件: 28 28, 60 |
194 | Genetic: Recombinant Adeno-Associated Virus Acid Alpha-Glucosidase | 1件: Alglucosidase alfa Alglucosidase alfa | 1件: D03207
D03207
| 1件: GAA GAA 💬 | 4件: Galactose metabolism Galactose metabolism, Lysosome, Metabolic pathways, Starch and sucrose metabolism 💬 | 1件: 256 256 |
195 | Genetic: recombinant adenovirus containing the ornithine transcarbamylase gene | 1件: Ornithine Ornithine | 1件: D08302
D08302
| - | - | 1件: 251 251 |
196 | Genetic: RNA analysis | - | - | - | - | 2件: 28 28, 60 |
197 | Genetic: RNA extraction | - | - | - | - | 1件: 113 113 |
198 | Genetic: RNA Sequencing | - | - | - | - | 1件: 84 84 |
199 | Genetic: scAAV8OTC | - | - | - | - | 1件: 251 251 |
200 | Genetic: somatropin | 1件: Somatotropin Somatotropin | 1件: D02691
D02691
| 1件: GHR GHR 💬 | 5件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Growth hormone synthesis, secretion and action, JAK-STAT signaling pathway, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway 💬 | 1件: 78 78 |
201 | Genetic: TPMT genotyping | - | - | - | - | 2件: 96 96, 97 |
202 | Genetic: UX701 | - | - | - | - | 1件: 171 171 |
203 | Genetically corrected cultured epidermal autograft (ATMP) | - | - | - | - | 1件: 36 36 |
204 | Genetically Engineered Hematopoietic Stem Progenitor Cells | - | - | - | - | 1件: 285 285 |
205 | Genetically Engineered Hematopoietic Stem/Progenitor Cells | - | - | - | - | 1件: 285 285 |
206 | Genetically modified autologous blood stem cells | - | - | - | - | 1件: 65 65 |
207 | Genicular nerve block | - | - | - | - | 1件: 107 107 |
208 | GENISTEIN | 1件: Genistein Genistein | 1件: D11680
D11680
| - | - | 2件: 19 19, 299 |
209 | Genistein (Unconjugated Isoflavones 100) | 1件: Genistein Genistein | 1件: D11680
D11680
| - | - | 1件: 299 299 |
210 | Genistein aglycone | 1件: Genistein Genistein | 1件: D11680
D11680
| - | - | 1件: 19 19 |
211 | Genisteine Plus 150 mg cpl formaat 1 18,7 x 6,4 mm 438 mg | - | - | - | - | 1件: 299 299 |
212 | GENOTONORM | - | - | - | - | 1件: 193 193 |
213 | Genotonorm Kabipen 5.3 mg polvo y disolvente para sol. inyectable (Marca internacional Genotropin) | 1件: Somatotropin Somatotropin | 1件: D02691
D02691
| 1件: GHR GHR 💬 | 5件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Growth hormone synthesis, secretion and action, JAK-STAT signaling pathway, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway 💬 | 1件: 78 78 |
214 | Genotonorm Kabipen 5.3 mg polvo y disolvente para solución inyectable (Marca internacional Genotropin) | 1件: Somatotropin Somatotropin | 1件: D02691
D02691
| 1件: GHR GHR 💬 | 5件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Growth hormone synthesis, secretion and action, JAK-STAT signaling pathway, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway 💬 | 1件: 78 78 |
215 | Genotonorm Miniquick 0,2 mg | - | - | - | - | 1件: 193 193 |
216 | Genotropin | - | - | - | - | 5件: 13 13, 78, 107, 187, 193 |
217 | Genotropin (human recombinant Growth hormone) | 1件: Somatotropin Somatotropin | 1件: D02691
D02691
| 1件: GHR GHR 💬 | 5件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Growth hormone synthesis, secretion and action, JAK-STAT signaling pathway, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway 💬 | 1件: 265 265 |
218 | Genotropin (PN-180,307) Somatropin | 1件: Somatotropin Somatotropin | 1件: D02691
D02691
| 1件: GHR GHR 💬 | 5件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Growth hormone synthesis, secretion and action, JAK-STAT signaling pathway, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway 💬 | 1件: 78 78 |
219 | GENOTROPIN (Somatropin) is a growth hormone treatment. It is an exact copy of the natural growth hormone that our bodies make. The main difference is that GENOTROPIN is man-made. | 1件: Somatotropin Somatotropin | 1件: D02691
D02691
| 1件: GHR GHR 💬 | 5件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Growth hormone synthesis, secretion and action, JAK-STAT signaling pathway, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway 💬 | 1件: 193 193 |
220 | Genotropin 12 mg | 1件: Somatotropin Somatotropin | 1件: D02691
D02691
| 1件: GHR GHR 💬 | 5件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Growth hormone synthesis, secretion and action, JAK-STAT signaling pathway, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway 💬 | 1件: 78 78 |
221 | GENOTROPIN 12 mg powder and solvent for solution for injection. | 1件: Somatotropin Somatotropin | 1件: D02691
D02691
| 1件: GHR GHR 💬 | 5件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Growth hormone synthesis, secretion and action, JAK-STAT signaling pathway, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway 💬 | 1件: 78 78 |
222 | Genotropin 12 mg/ml | 1件: Somatotropin Somatotropin | 1件: D02691
D02691
| 1件: GHR GHR 💬 | 5件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Growth hormone synthesis, secretion and action, JAK-STAT signaling pathway, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway 💬 | 1件: 78 78 |
223 | Genotropin 12mg | 1件: Somatotropin Somatotropin | 1件: D02691
D02691
| 1件: GHR GHR 💬 | 5件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Growth hormone synthesis, secretion and action, JAK-STAT signaling pathway, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway 💬 | 3件: 74 74, 75, 78 |
224 | Genotropin 5 mg/ml | 1件: Somatotropin Somatotropin | 1件: D02691
D02691
| 1件: GHR GHR 💬 | 5件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Growth hormone synthesis, secretion and action, JAK-STAT signaling pathway, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway 💬 | 1件: 78 78 |
225 | Genotropin 5.3 mg in injection system Genotropin pen | 1件: Somatotropin Somatotropin | 1件: D02691
D02691
| 1件: GHR GHR 💬 | 5件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Growth hormone synthesis, secretion and action, JAK-STAT signaling pathway, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway 💬 | 1件: 78 78 |
226 | Genotropin 5.3mg | 1件: Somatotropin Somatotropin | 1件: D02691
D02691
| 1件: GHR GHR 💬 | 5件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Growth hormone synthesis, secretion and action, JAK-STAT signaling pathway, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway 💬 | 3件: 74 74, 75, 78 |
227 | Genotropin GoQuick | 1件: Somatotropin Somatotropin | 1件: D02691
D02691
| 1件: GHR GHR 💬 | 5件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Growth hormone synthesis, secretion and action, JAK-STAT signaling pathway, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway 💬 | 1件: 78 78 |
228 | Genotropin Mark VII pen | 1件: Somatotropin Somatotropin | 1件: D02691
D02691
| 1件: GHR GHR 💬 | 5件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Growth hormone synthesis, secretion and action, JAK-STAT signaling pathway, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway 💬 | 1件: 78 78 |
229 | Genotropin Miniqu | 1件: Somatotropin Somatotropin | 1件: D02691
D02691
| 1件: GHR GHR 💬 | 5件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Growth hormone synthesis, secretion and action, JAK-STAT signaling pathway, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway 💬 | 3件: 74 74, 75, 78 |
230 | Genotropin MiniQuick | - | - | - | - | 1件: 78 78 |
231 | Genotropin Miniquick 0.2mg | 1件: Somatotropin Somatotropin | 1件: D02691
D02691
| 1件: GHR GHR 💬 | 5件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Growth hormone synthesis, secretion and action, JAK-STAT signaling pathway, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway 💬 | 3件: 74 74, 75, 78 |
232 | Genotropin Miniquick 0.4mg | 1件: Somatotropin Somatotropin | 1件: D02691
D02691
| 1件: GHR GHR 💬 | 5件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Growth hormone synthesis, secretion and action, JAK-STAT signaling pathway, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway 💬 | 3件: 74 74, 75, 78 |
233 | Genotropin miniquick 0.5 mg, injection | - | - | - | - | 1件: 78 78 |
234 | Genotropin Miniquick 0.6mg | 1件: Somatotropin Somatotropin | 1件: D02691
D02691
| 1件: GHR GHR 💬 | 5件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Growth hormone synthesis, secretion and action, JAK-STAT signaling pathway, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway 💬 | 3件: 74 74, 75, 78 |
235 | Genotropin Miniquick 0.8mg | 1件: Somatotropin Somatotropin | 1件: D02691
D02691
| 1件: GHR GHR 💬 | 5件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Growth hormone synthesis, secretion and action, JAK-STAT signaling pathway, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway 💬 | 3件: 74 74, 75, 78 |
236 | Genotropin Miniquick 1.0mg | 1件: Somatotropin Somatotropin | 1件: D02691
D02691
| 1件: GHR GHR 💬 | 5件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Growth hormone synthesis, secretion and action, JAK-STAT signaling pathway, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway 💬 | 3件: 74 74, 75, 78 |
237 | Genotropin Miniquick 1.2mg | 1件: Somatotropin Somatotropin | 1件: D02691
D02691
| 1件: GHR GHR 💬 | 5件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Growth hormone synthesis, secretion and action, JAK-STAT signaling pathway, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway 💬 | 3件: 74 74, 75, 78 |
238 | GENOTROPIN*1TBF 5,3MG (16UI) | 1件: Somatotropin Somatotropin | 1件: D02691
D02691
| 1件: GHR GHR 💬 | 5件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Growth hormone synthesis, secretion and action, JAK-STAT signaling pathway, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway 💬 | 1件: 274 274 |
239 | Genotropin, Genotropin MiniQuick | 1件: Somatotropin Somatotropin | 1件: D02691
D02691
| 1件: GHR GHR 💬 | 5件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Growth hormone synthesis, secretion and action, JAK-STAT signaling pathway, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway 💬 | 1件: 78 78 |
240 | Genotropin/GENOTONORM® | - | - | - | - | 1件: 78 78 |
241 | Genotropin® | 1件: Somatotropin Somatotropin | 1件: D02691
D02691
| 1件: GHR GHR 💬 | 5件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Growth hormone synthesis, secretion and action, JAK-STAT signaling pathway, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway 💬 | 1件: 78 78 |
242 | Genoxal | - | - | - | - | 1件: 222 222 |
243 | Gentamicin | 1件: Gentamicin Gentamicin | 2件: D01063
D01063
,
D08013
| - | - | 3件: 36 36, 113, 299 |
244 | Gentamicin infusions twice a week for six months | 1件: Gentamicin Gentamicin | 2件: D01063
D01063
,
D08013
| - | - | 1件: 113 113 |
245 | Gentamicin Sulfate | 2件: Gentamicin Gentamicin, Sulfate ion | 2件: D01063
D01063
,
D08013
| - | - | 1件: 36 36 |
246 | Gentamicin sulfate 0.1% ointment | 2件: Gentamicin Gentamicin, Sulfate ion | 2件: D01063
D01063
,
D08013
| - | - | 1件: 36 36 |
247 | Gentamicin Sulfate, Injectable | 2件: Gentamicin Gentamicin, Sulfate ion | 2件: D01063
D01063
,
D08013
| - | - | 1件: 36 36 |
248 | GentleCath™ Air catheter | - | - | - | - | 1件: 13 13 |
249 | Genz-112638 | - | - | - | - | 1件: 19 19 |
250 | GENZ-682452 | 1件: Venglustat Venglustat | 1件: D11633
D11633
| 1件: UGCG UGCG 💬 | 2件: Metabolic pathways Metabolic pathways, Sphingolipid metabolism 💬 | 3件: 6 6, 19, 67 |
251 | Genz-682452-AA | 1件: Venglustat Venglustat | 1件: D11633
D11633
| 1件: UGCG UGCG 💬 | 2件: Metabolic pathways Metabolic pathways, Sphingolipid metabolism 💬 | 1件: 19 19 |
252 | Genz-682452-AU | 1件: Venglustat Venglustat | 1件: D11633
D11633
| 1件: UGCG UGCG 💬 | 2件: Metabolic pathways Metabolic pathways, Sphingolipid metabolism 💬 | 3件: 6 6, 19, 67 |
253 | Gerilimzumab | - | - | - | - | 1件: 46 46 |
254 | Gernebcin | - | - | - | - | 1件: 299 299 |
255 | Gernebcin 80 mg | - | - | - | - | 1件: 299 299 |
256 | Gevokizumab | 1件: Gevokizumab Gevokizumab | 1件: D09911
D09911
| 1件: IL1B IL1B 💬 | 44件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, African trypanosomiasis, Alcoholic liver disease, Alzheimer disease, Amoebiasis, Antifolate resistance, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Cytosolic DNA-sensing pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Herpes simplex virus 1 infection, Human cytomegalovirus infection, IL-17 signaling pathway, Inflammatory bowel disease, Inflammatory mediator regulation of TRP channels, Influenza A, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, Measles, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Rheumatoid arthritis, Salmonella infection, Shigellosis, TNF signaling pathway, Th17 cell differentiation, Toll-like receptor signaling pathway, Tuberculosis, Type I diabetes mellitus, Yersinia infection 💬 | 4件: 41 41, 50, 56, 269 |
257 | Gevokizumab open-label | 1件: Gevokizumab Gevokizumab | 1件: D09911
D09911
| 1件: IL1B IL1B 💬 | 44件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, African trypanosomiasis, Alcoholic liver disease, Alzheimer disease, Amoebiasis, Antifolate resistance, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Cytosolic DNA-sensing pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Herpes simplex virus 1 infection, Human cytomegalovirus infection, IL-17 signaling pathway, Inflammatory bowel disease, Inflammatory mediator regulation of TRP channels, Influenza A, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, Measles, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Rheumatoid arthritis, Salmonella infection, Shigellosis, TNF signaling pathway, Th17 cell differentiation, Toll-like receptor signaling pathway, Tuberculosis, Type I diabetes mellitus, Yersinia infection 💬 | 1件: 269 269 |
258 | GFB-887 | - | - | - | - | 1件: 222 222 |
259 | GFI 38518168-AEK-B-007 | - | - | - | - | 1件: 46 46 |
260 | GFT505 | - | - | - | - | 1件: 93 93 |
261 | GH | - | - | - | - | 1件: 3 3 |
262 | GH sampling - every 20 min over 24 hours | - | - | - | - | 1件: 78 78 |
263 | GH substitution | - | - | - | - | 1件: 78 78 |
264 | Ghrelin | 1件: Lenomorelin Lenomorelin | - | - | - | 6件: 6 6, 78, 193, 201, 202, 299 |
265 | GHRH | 1件: Somatorelin Somatorelin | 1件: D08523
D08523
| 1件: GHRHR GHRHR 💬 | 2件: Growth hormone synthesis, secretion and action Growth hormone synthesis, secretion and action, Neuroactive ligand-receptor interaction 💬 | 1件: 78 78 |
266 | GHRH/arginine stimulation testing | 2件: Arginine Arginine, Somatorelin | 2件: D02982
D02982
,
D08523
| 1件: GHRHR GHRHR 💬 | 2件: Growth hormone synthesis, secretion and action Growth hormone synthesis, secretion and action, Neuroactive ligand-receptor interaction 💬 | 1件: 78 78 |
267 | GI-270384 | - | - | - | - | 1件: 97 97 |
268 | Gilenya | - | - | - | - | 3件: 2 2, 13, 14 |
269 | GILENYA - 0.25 MG - CAPSULE RIGIDE - USO ORALE | 1件: Fingolimod Fingolimod | 1件: D10001
D10001
| 1件: S1PR1 S1PR1 💬 | 3件: FoxO signaling pathway FoxO signaling pathway, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway 💬 | 1件: 13 13 |
270 | GILENYA - 0.5 MG - CAPSULE RIGIDE - USO ORALE | 1件: Fingolimod Fingolimod | 1件: D10001
D10001
| 1件: S1PR1 S1PR1 💬 | 3件: FoxO signaling pathway FoxO signaling pathway, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway 💬 | 1件: 13 13 |
271 | GILENYA - 0.5 MG - CAPSULE RIGIDE - USO ORALE - BLISTER DIVISIBILE PER DOSE UNITARIA(PVC/PVDC/ALU) SCATOLA DA 7X1 CAPSULE | 1件: Fingolimod Fingolimod | 1件: D10001
D10001
| 1件: S1PR1 S1PR1 💬 | 3件: FoxO signaling pathway FoxO signaling pathway, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway 💬 | 1件: 13 13 |
272 | GILENYA - 0.5 MG - CAPSULE RIGIDE - USO ORALE - BLISTER(PVC/PVDC/ALU) SCATOLA DA 28 CAPSULE | 1件: Fingolimod Fingolimod | 1件: D10001
D10001
| 1件: S1PR1 S1PR1 💬 | 3件: FoxO signaling pathway FoxO signaling pathway, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway 💬 | 1件: 13 13 |
273 | Gilenya / Imusera | 1件: Fingolimod Fingolimod | 1件: D10001
D10001
| 1件: S1PR1 S1PR1 💬 | 3件: FoxO signaling pathway FoxO signaling pathway, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway 💬 | 1件: 13 13 |
274 | GILENYA 0,5 mg cápsulas duras | 1件: Fingolimod Fingolimod | 1件: D10001
D10001
| 1件: S1PR1 S1PR1 💬 | 3件: FoxO signaling pathway FoxO signaling pathway, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway 💬 | 1件: 14 14 |
275 | Gilenya 0,5 mg Hartkapseln | 1件: Fingolimod Fingolimod | 1件: D10001
D10001
| 1件: S1PR1 S1PR1 💬 | 3件: FoxO signaling pathway FoxO signaling pathway, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway 💬 | 1件: 13 13 |
276 | Gilenya® | - | - | - | - | 1件: 13 13 |
277 | Gileyna | - | - | - | - | 1件: 13 13 |
278 | GILT-rhGAA | - | - | - | - | 1件: 256 256 |
279 | Ginger | 1件: Ginger Ginger | 1件: D06744
D06744
| - | - | 2件: 46 46, 271 |
280 | Ginkgo | 1件: Ginkgo biloba Ginkgo biloba | - | - | - | 5件: 6 6, 13, 18, 47, 90 |
281 | Ginkgo biloba | 1件: Ginkgo biloba Ginkgo biloba | - | - | - | 4件: 13 13, 18, 47, 90 |
282 | Ginkgo biloba pills sig: 300mg/tid | 1件: Ginkgo biloba Ginkgo biloba | - | - | - | 1件: 90 90 |
283 | Ginseng | 1件: Ginseng Ginseng | 1件: D06772
D06772
| - | - | 3件: 13 13, 46, 53 |
284 | Ginsenoside | 1件: Ginsenosides Ginsenosides | - | - | - | 1件: 46 46 |
285 | GIP | - | - | - | - | 1件: 299 299 |
286 | Giving DHA-rich supplement | - | - | - | - | 1件: 299 299 |
287 | Givinostat | 1件: Givinostat Givinostat | - | - | - | 2件: 107 107, 113 |
288 | Givinostat (hydrochloride monohydrate) | 1件: Givinostat Givinostat | - | - | - | 1件: 113 113 |
289 | Givinostat (hydrochloride-monohydrate) | 1件: Givinostat Givinostat | - | - | - | 1件: 107 107 |
290 | GIVINOSTAT (hyrochloride monohydrate) | 1件: Givinostat Givinostat | - | - | - | 1件: 113 113 |
291 | Givinostat (idrocloruro monoidrato) | 1件: Givinostat Givinostat | - | - | - | 1件: 113 113 |
292 | Givosiran | 1件: Givosiran Givosiran | 1件: D11702
D11702
| 1件: ALAS1 ALAS1 💬 | 4件: Biosynthesis of cofactors Biosynthesis of cofactors, Glycine, serine and threonine metabolism, Metabolic pathways, Porphyrin metabolism 💬 | 1件: 254 254 |
293 | Givosiran (ALN-AS1) | 1件: Givosiran Givosiran | 1件: D11702
D11702
| 1件: ALAS1 ALAS1 💬 | 4件: Biosynthesis of cofactors Biosynthesis of cofactors, Glycine, serine and threonine metabolism, Metabolic pathways, Porphyrin metabolism 💬 | 1件: 254 254 |
294 | GKT137831 | - | - | - | - | 2件: 85 85, 93 |
295 | GL701 | - | - | - | - | 1件: 49 49 |
296 | GLA | - | - | - | - | 2件: 13 13, 19 |
297 | GLA genetic sequencing. | - | - | - | - | 1件: 19 19 |
298 | Glargine | - | - | - | - | 1件: 299 299 |
299 | Glargine insulin | - | - | - | - | 1件: 299 299 |
300 | Glassia | 1件: Alpha-1-proteinase inhibitor Alpha-1-proteinase inhibitor | - | - | - | 1件: 231 231 |
301 | Glatiramer | 1件: Glatiramer Glatiramer | 1件: D04318
D04318
| 20件: HLA-A HLA-A, HLA-B, HLA-C, HLA-DMA, HLA-DMB, HLA-DOA, HLA-DOB, HLA-DPA1, HLA-DPB1, HLA-DQA1, HLA-DQA2, HLA-DQB1, HLA-DRA, HLA-DRB1, HLA-DRB3, HLA-DRB4, HLA-DRB5, HLA-E, HLA-F, HLA-G 💬 | 32件: Allograft rejection Allograft rejection, Antigen processing and presentation, Asthma, Autoimmune thyroid disease, Cell adhesion molecules, Cellular senescence, Endocytosis, Epstein-Barr virus infection, Graft-versus-host disease, Hematopoietic cell lineage, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Inflammatory bowel disease, Influenza A, Intestinal immune network for IgA production, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Natural killer cell mediated cytotoxicity, Phagosome, Rheumatoid arthritis, Staphylococcus aureus infection, Systemic lupus erythematosus, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Viral carcinogenesis, Viral myocarditis 💬 | 4件: 2 2, 13, 96, 156 |
302 | GLATIRAMER ACETATE | 2件: Acetate Acetate, Glatiramer | 1件: D04318
D04318
| 20件: HLA-A HLA-A, HLA-B, HLA-C, HLA-DMA, HLA-DMB, HLA-DOA, HLA-DOB, HLA-DPA1, HLA-DPB1, HLA-DQA1, HLA-DQA2, HLA-DQB1, HLA-DRA, HLA-DRB1, HLA-DRB3, HLA-DRB4, HLA-DRB5, HLA-E, HLA-F, HLA-G 💬 | 32件: Allograft rejection Allograft rejection, Antigen processing and presentation, Asthma, Autoimmune thyroid disease, Cell adhesion molecules, Cellular senescence, Endocytosis, Epstein-Barr virus infection, Graft-versus-host disease, Hematopoietic cell lineage, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Inflammatory bowel disease, Influenza A, Intestinal immune network for IgA production, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Natural killer cell mediated cytotoxicity, Phagosome, Rheumatoid arthritis, Staphylococcus aureus infection, Systemic lupus erythematosus, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Viral carcinogenesis, Viral myocarditis 💬 | 3件: 13 13, 96, 156 |
303 | Glatiramer Acetate (Copaxone®) | 2件: Acetate Acetate, Glatiramer | 1件: D04318
D04318
| 20件: HLA-A HLA-A, HLA-B, HLA-C, HLA-DMA, HLA-DMB, HLA-DOA, HLA-DOB, HLA-DPA1, HLA-DPB1, HLA-DQA1, HLA-DQA2, HLA-DQB1, HLA-DRA, HLA-DRB1, HLA-DRB3, HLA-DRB4, HLA-DRB5, HLA-E, HLA-F, HLA-G 💬 | 32件: Allograft rejection Allograft rejection, Antigen processing and presentation, Asthma, Autoimmune thyroid disease, Cell adhesion molecules, Cellular senescence, Endocytosis, Epstein-Barr virus infection, Graft-versus-host disease, Hematopoietic cell lineage, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Inflammatory bowel disease, Influenza A, Intestinal immune network for IgA production, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Natural killer cell mediated cytotoxicity, Phagosome, Rheumatoid arthritis, Staphylococcus aureus infection, Systemic lupus erythematosus, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Viral carcinogenesis, Viral myocarditis 💬 | 2件: 13 13, 156 |
304 | Glatiramer Acetate (DB) | 2件: Acetate Acetate, Glatiramer | 1件: D04318
D04318
| 20件: HLA-A HLA-A, HLA-B, HLA-C, HLA-DMA, HLA-DMB, HLA-DOA, HLA-DOB, HLA-DPA1, HLA-DPB1, HLA-DQA1, HLA-DQA2, HLA-DQB1, HLA-DRA, HLA-DRB1, HLA-DRB3, HLA-DRB4, HLA-DRB5, HLA-E, HLA-F, HLA-G 💬 | 32件: Allograft rejection Allograft rejection, Antigen processing and presentation, Asthma, Autoimmune thyroid disease, Cell adhesion molecules, Cellular senescence, Endocytosis, Epstein-Barr virus infection, Graft-versus-host disease, Hematopoietic cell lineage, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Inflammatory bowel disease, Influenza A, Intestinal immune network for IgA production, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Natural killer cell mediated cytotoxicity, Phagosome, Rheumatoid arthritis, Staphylococcus aureus infection, Systemic lupus erythematosus, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Viral carcinogenesis, Viral myocarditis 💬 | 1件: 13 13 |
305 | Glatiramer Acetate (GA) | 2件: Acetate Acetate, Glatiramer | 1件: D04318
D04318
| 20件: HLA-A HLA-A, HLA-B, HLA-C, HLA-DMA, HLA-DMB, HLA-DOA, HLA-DOB, HLA-DPA1, HLA-DPB1, HLA-DQA1, HLA-DQA2, HLA-DQB1, HLA-DRA, HLA-DRB1, HLA-DRB3, HLA-DRB4, HLA-DRB5, HLA-E, HLA-F, HLA-G 💬 | 32件: Allograft rejection Allograft rejection, Antigen processing and presentation, Asthma, Autoimmune thyroid disease, Cell adhesion molecules, Cellular senescence, Endocytosis, Epstein-Barr virus infection, Graft-versus-host disease, Hematopoietic cell lineage, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Inflammatory bowel disease, Influenza A, Intestinal immune network for IgA production, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Natural killer cell mediated cytotoxicity, Phagosome, Rheumatoid arthritis, Staphylococcus aureus infection, Systemic lupus erythematosus, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Viral carcinogenesis, Viral myocarditis 💬 | 1件: 13 13 |
306 | Glatiramer Acetate (GA) 40 mg | 2件: Acetate Acetate, Glatiramer | 1件: D04318
D04318
| 20件: HLA-A HLA-A, HLA-B, HLA-C, HLA-DMA, HLA-DMB, HLA-DOA, HLA-DOB, HLA-DPA1, HLA-DPB1, HLA-DQA1, HLA-DQA2, HLA-DQB1, HLA-DRA, HLA-DRB1, HLA-DRB3, HLA-DRB4, HLA-DRB5, HLA-E, HLA-F, HLA-G 💬 | 32件: Allograft rejection Allograft rejection, Antigen processing and presentation, Asthma, Autoimmune thyroid disease, Cell adhesion molecules, Cellular senescence, Endocytosis, Epstein-Barr virus infection, Graft-versus-host disease, Hematopoietic cell lineage, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Inflammatory bowel disease, Influenza A, Intestinal immune network for IgA production, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Natural killer cell mediated cytotoxicity, Phagosome, Rheumatoid arthritis, Staphylococcus aureus infection, Systemic lupus erythematosus, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Viral carcinogenesis, Viral myocarditis 💬 | 1件: 13 13 |
307 | Glatiramer Acetate (GTR) | 2件: Acetate Acetate, Glatiramer | 1件: D04318
D04318
| 20件: HLA-A HLA-A, HLA-B, HLA-C, HLA-DMA, HLA-DMB, HLA-DOA, HLA-DOB, HLA-DPA1, HLA-DPB1, HLA-DQA1, HLA-DQA2, HLA-DQB1, HLA-DRA, HLA-DRB1, HLA-DRB3, HLA-DRB4, HLA-DRB5, HLA-E, HLA-F, HLA-G 💬 | 32件: Allograft rejection Allograft rejection, Antigen processing and presentation, Asthma, Autoimmune thyroid disease, Cell adhesion molecules, Cellular senescence, Endocytosis, Epstein-Barr virus infection, Graft-versus-host disease, Hematopoietic cell lineage, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Inflammatory bowel disease, Influenza A, Intestinal immune network for IgA production, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Natural killer cell mediated cytotoxicity, Phagosome, Rheumatoid arthritis, Staphylococcus aureus infection, Systemic lupus erythematosus, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Viral carcinogenesis, Viral myocarditis 💬 | 1件: 13 13 |
308 | Glatiramer Acetate (OL) | 2件: Acetate Acetate, Glatiramer | 1件: D04318
D04318
| 20件: HLA-A HLA-A, HLA-B, HLA-C, HLA-DMA, HLA-DMB, HLA-DOA, HLA-DOB, HLA-DPA1, HLA-DPB1, HLA-DQA1, HLA-DQA2, HLA-DQB1, HLA-DRA, HLA-DRB1, HLA-DRB3, HLA-DRB4, HLA-DRB5, HLA-E, HLA-F, HLA-G 💬 | 32件: Allograft rejection Allograft rejection, Antigen processing and presentation, Asthma, Autoimmune thyroid disease, Cell adhesion molecules, Cellular senescence, Endocytosis, Epstein-Barr virus infection, Graft-versus-host disease, Hematopoietic cell lineage, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Inflammatory bowel disease, Influenza A, Intestinal immune network for IgA production, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Natural killer cell mediated cytotoxicity, Phagosome, Rheumatoid arthritis, Staphylococcus aureus infection, Systemic lupus erythematosus, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Viral carcinogenesis, Viral myocarditis 💬 | 1件: 13 13 |
309 | Glatiramer acetate 150mg enteric coated tablets | 2件: Acetate Acetate, Glatiramer | 1件: D04318
D04318
| 20件: HLA-A HLA-A, HLA-B, HLA-C, HLA-DMA, HLA-DMB, HLA-DOA, HLA-DOB, HLA-DPA1, HLA-DPB1, HLA-DQA1, HLA-DQA2, HLA-DQB1, HLA-DRA, HLA-DRB1, HLA-DRB3, HLA-DRB4, HLA-DRB5, HLA-E, HLA-F, HLA-G 💬 | 32件: Allograft rejection Allograft rejection, Antigen processing and presentation, Asthma, Autoimmune thyroid disease, Cell adhesion molecules, Cellular senescence, Endocytosis, Epstein-Barr virus infection, Graft-versus-host disease, Hematopoietic cell lineage, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Inflammatory bowel disease, Influenza A, Intestinal immune network for IgA production, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Natural killer cell mediated cytotoxicity, Phagosome, Rheumatoid arthritis, Staphylococcus aureus infection, Systemic lupus erythematosus, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Viral carcinogenesis, Viral myocarditis 💬 | 1件: 13 13 |
310 | Glatiramer acetate 150mg enteric-coated (gastro-resistant) tablets | 2件: Acetate Acetate, Glatiramer | 1件: D04318
D04318
| 20件: HLA-A HLA-A, HLA-B, HLA-C, HLA-DMA, HLA-DMB, HLA-DOA, HLA-DOB, HLA-DPA1, HLA-DPB1, HLA-DQA1, HLA-DQA2, HLA-DQB1, HLA-DRA, HLA-DRB1, HLA-DRB3, HLA-DRB4, HLA-DRB5, HLA-E, HLA-F, HLA-G 💬 | 32件: Allograft rejection Allograft rejection, Antigen processing and presentation, Asthma, Autoimmune thyroid disease, Cell adhesion molecules, Cellular senescence, Endocytosis, Epstein-Barr virus infection, Graft-versus-host disease, Hematopoietic cell lineage, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Inflammatory bowel disease, Influenza A, Intestinal immune network for IgA production, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Natural killer cell mediated cytotoxicity, Phagosome, Rheumatoid arthritis, Staphylococcus aureus infection, Systemic lupus erythematosus, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Viral carcinogenesis, Viral myocarditis 💬 | 1件: 13 13 |
311 | Glatiramer acetate 20 mg | 2件: Acetate Acetate, Glatiramer | 1件: D04318
D04318
| 20件: HLA-A HLA-A, HLA-B, HLA-C, HLA-DMA, HLA-DMB, HLA-DOA, HLA-DOB, HLA-DPA1, HLA-DPB1, HLA-DQA1, HLA-DQA2, HLA-DQB1, HLA-DRA, HLA-DRB1, HLA-DRB3, HLA-DRB4, HLA-DRB5, HLA-E, HLA-F, HLA-G 💬 | 32件: Allograft rejection Allograft rejection, Antigen processing and presentation, Asthma, Autoimmune thyroid disease, Cell adhesion molecules, Cellular senescence, Endocytosis, Epstein-Barr virus infection, Graft-versus-host disease, Hematopoietic cell lineage, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Inflammatory bowel disease, Influenza A, Intestinal immune network for IgA production, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Natural killer cell mediated cytotoxicity, Phagosome, Rheumatoid arthritis, Staphylococcus aureus infection, Systemic lupus erythematosus, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Viral carcinogenesis, Viral myocarditis 💬 | 1件: 13 13 |
312 | Glatiramer acetate 20 mg, with mitoxantrone | 3件: Acetate Acetate, Glatiramer, Mitoxantrone | 3件: D02166
D02166
,
D04318
,
D08224
| 22件: HLA-A HLA-A, HLA-B, HLA-C, HLA-DMA, HLA-DMB, HLA-DOA, HLA-DOB, HLA-DPA1, HLA-DPB1, HLA-DQA1, HLA-DQA2, HLA-DQB1, HLA-DRA, HLA-DRB1, HLA-DRB3, HLA-DRB4, HLA-DRB5, HLA-E, HLA-F, HLA-G, TOP2A, TOP2B 💬 | 33件: Allograft rejection Allograft rejection, Antigen processing and presentation, Asthma, Autoimmune thyroid disease, Cell adhesion molecules, Cellular senescence, Endocytosis, Epstein-Barr virus infection, Graft-versus-host disease, Hematopoietic cell lineage, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Inflammatory bowel disease, Influenza A, Intestinal immune network for IgA production, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Natural killer cell mediated cytotoxicity, Phagosome, Platinum drug resistance, Rheumatoid arthritis, Staphylococcus aureus infection, Systemic lupus erythematosus, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Viral carcinogenesis, Viral myocarditis 💬 | 1件: 13 13 |
313 | Glatiramer Acetate 20 mg/0.5 mL | 2件: Acetate Acetate, Glatiramer | 1件: D04318
D04318
| 20件: HLA-A HLA-A, HLA-B, HLA-C, HLA-DMA, HLA-DMB, HLA-DOA, HLA-DOB, HLA-DPA1, HLA-DPB1, HLA-DQA1, HLA-DQA2, HLA-DQB1, HLA-DRA, HLA-DRB1, HLA-DRB3, HLA-DRB4, HLA-DRB5, HLA-E, HLA-F, HLA-G 💬 | 32件: Allograft rejection Allograft rejection, Antigen processing and presentation, Asthma, Autoimmune thyroid disease, Cell adhesion molecules, Cellular senescence, Endocytosis, Epstein-Barr virus infection, Graft-versus-host disease, Hematopoietic cell lineage, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Inflammatory bowel disease, Influenza A, Intestinal immune network for IgA production, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Natural killer cell mediated cytotoxicity, Phagosome, Rheumatoid arthritis, Staphylococcus aureus infection, Systemic lupus erythematosus, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Viral carcinogenesis, Viral myocarditis 💬 | 1件: 13 13 |
314 | Glatiramer acetate 40 mg | 2件: Acetate Acetate, Glatiramer | 1件: D04318
D04318
| 20件: HLA-A HLA-A, HLA-B, HLA-C, HLA-DMA, HLA-DMB, HLA-DOA, HLA-DOB, HLA-DPA1, HLA-DPB1, HLA-DQA1, HLA-DQA2, HLA-DQB1, HLA-DRA, HLA-DRB1, HLA-DRB3, HLA-DRB4, HLA-DRB5, HLA-E, HLA-F, HLA-G 💬 | 32件: Allograft rejection Allograft rejection, Antigen processing and presentation, Asthma, Autoimmune thyroid disease, Cell adhesion molecules, Cellular senescence, Endocytosis, Epstein-Barr virus infection, Graft-versus-host disease, Hematopoietic cell lineage, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Inflammatory bowel disease, Influenza A, Intestinal immune network for IgA production, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Natural killer cell mediated cytotoxicity, Phagosome, Rheumatoid arthritis, Staphylococcus aureus infection, Systemic lupus erythematosus, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Viral carcinogenesis, Viral myocarditis 💬 | 1件: 13 13 |
315 | Glatiramer Acetate [GA] | 2件: Acetate Acetate, Glatiramer | 1件: D04318
D04318
| 20件: HLA-A HLA-A, HLA-B, HLA-C, HLA-DMA, HLA-DMB, HLA-DOA, HLA-DOB, HLA-DPA1, HLA-DPB1, HLA-DQA1, HLA-DQA2, HLA-DQB1, HLA-DRA, HLA-DRB1, HLA-DRB3, HLA-DRB4, HLA-DRB5, HLA-E, HLA-F, HLA-G 💬 | 32件: Allograft rejection Allograft rejection, Antigen processing and presentation, Asthma, Autoimmune thyroid disease, Cell adhesion molecules, Cellular senescence, Endocytosis, Epstein-Barr virus infection, Graft-versus-host disease, Hematopoietic cell lineage, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Inflammatory bowel disease, Influenza A, Intestinal immune network for IgA production, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Natural killer cell mediated cytotoxicity, Phagosome, Rheumatoid arthritis, Staphylococcus aureus infection, Systemic lupus erythematosus, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Viral carcinogenesis, Viral myocarditis 💬 | 1件: 13 13 |
316 | Glatiramer acetate injection with oral cetirizine hydrochloride | 3件: Acetate Acetate, Cetirizine, Glatiramer | 3件: D00664
D00664
,
D04318
,
D07662
| 21件: HLA-A HLA-A, HLA-B, HLA-C, HLA-DMA, HLA-DMB, HLA-DOA, HLA-DOB, HLA-DPA1, HLA-DPB1, HLA-DQA1, HLA-DQA2, HLA-DQB1, HLA-DRA, HLA-DRB1, HLA-DRB3, HLA-DRB4, HLA-DRB5, HLA-E, HLA-F, HLA-G, HRH1 💬 | 35件: Allograft rejection Allograft rejection, Antigen processing and presentation, Asthma, Autoimmune thyroid disease, Calcium signaling pathway, Cell adhesion molecules, Cellular senescence, Endocytosis, Epstein-Barr virus infection, Graft-versus-host disease, Hematopoietic cell lineage, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Inflammatory bowel disease, Inflammatory mediator regulation of TRP channels, Influenza A, Intestinal immune network for IgA production, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Natural killer cell mediated cytotoxicity, Neuroactive ligand-receptor interaction, Phagosome, Rheumatoid arthritis, Staphylococcus aureus infection, Systemic lupus erythematosus, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Viral carcinogenesis, Viral myocarditis 💬 | 1件: 13 13 |
317 | Glatiramer acetate with minocycline | 3件: Acetate Acetate, Glatiramer, Minocycline | 3件: D00850
D00850
,
D04318
,
D05045
| 20件: HLA-A HLA-A, HLA-B, HLA-C, HLA-DMA, HLA-DMB, HLA-DOA, HLA-DOB, HLA-DPA1, HLA-DPB1, HLA-DQA1, HLA-DQA2, HLA-DQB1, HLA-DRA, HLA-DRB1, HLA-DRB3, HLA-DRB4, HLA-DRB5, HLA-E, HLA-F, HLA-G 💬 | 32件: Allograft rejection Allograft rejection, Antigen processing and presentation, Asthma, Autoimmune thyroid disease, Cell adhesion molecules, Cellular senescence, Endocytosis, Epstein-Barr virus infection, Graft-versus-host disease, Hematopoietic cell lineage, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Inflammatory bowel disease, Influenza A, Intestinal immune network for IgA production, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Natural killer cell mediated cytotoxicity, Phagosome, Rheumatoid arthritis, Staphylococcus aureus infection, Systemic lupus erythematosus, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Viral carcinogenesis, Viral myocarditis 💬 | 1件: 13 13 |
318 | Glatiramer acetate, (Copaxone®) | 2件: Acetate Acetate, Glatiramer | 1件: D04318
D04318
| 20件: HLA-A HLA-A, HLA-B, HLA-C, HLA-DMA, HLA-DMB, HLA-DOA, HLA-DOB, HLA-DPA1, HLA-DPB1, HLA-DQA1, HLA-DQA2, HLA-DQB1, HLA-DRA, HLA-DRB1, HLA-DRB3, HLA-DRB4, HLA-DRB5, HLA-E, HLA-F, HLA-G 💬 | 32件: Allograft rejection Allograft rejection, Antigen processing and presentation, Asthma, Autoimmune thyroid disease, Cell adhesion molecules, Cellular senescence, Endocytosis, Epstein-Barr virus infection, Graft-versus-host disease, Hematopoietic cell lineage, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Inflammatory bowel disease, Influenza A, Intestinal immune network for IgA production, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Natural killer cell mediated cytotoxicity, Phagosome, Rheumatoid arthritis, Staphylococcus aureus infection, Systemic lupus erythematosus, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Viral carcinogenesis, Viral myocarditis 💬 | 1件: 13 13 |
319 | Glatiramer Acetate, IFN-beta 1a (IM), IFN-beta 1a (Subcutaneous), and IFN-beta 1b | 2件: Acetate Acetate, Glatiramer | 1件: D04318
D04318
| 20件: HLA-A HLA-A, HLA-B, HLA-C, HLA-DMA, HLA-DMB, HLA-DOA, HLA-DOB, HLA-DPA1, HLA-DPB1, HLA-DQA1, HLA-DQA2, HLA-DQB1, HLA-DRA, HLA-DRB1, HLA-DRB3, HLA-DRB4, HLA-DRB5, HLA-E, HLA-F, HLA-G 💬 | 32件: Allograft rejection Allograft rejection, Antigen processing and presentation, Asthma, Autoimmune thyroid disease, Cell adhesion molecules, Cellular senescence, Endocytosis, Epstein-Barr virus infection, Graft-versus-host disease, Hematopoietic cell lineage, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Inflammatory bowel disease, Influenza A, Intestinal immune network for IgA production, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Natural killer cell mediated cytotoxicity, Phagosome, Rheumatoid arthritis, Staphylococcus aureus infection, Systemic lupus erythematosus, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Viral carcinogenesis, Viral myocarditis 💬 | 1件: 13 13 |
320 | Glatiramer Acetate, N-Acetylcysteine | 3件: Acetate Acetate, Acetylcysteine, Glatiramer | 2件: D00221
D00221
,
D04318
| 20件: HLA-A HLA-A, HLA-B, HLA-C, HLA-DMA, HLA-DMB, HLA-DOA, HLA-DOB, HLA-DPA1, HLA-DPB1, HLA-DQA1, HLA-DQA2, HLA-DQB1, HLA-DRA, HLA-DRB1, HLA-DRB3, HLA-DRB4, HLA-DRB5, HLA-E, HLA-F, HLA-G 💬 | 32件: Allograft rejection Allograft rejection, Antigen processing and presentation, Asthma, Autoimmune thyroid disease, Cell adhesion molecules, Cellular senescence, Endocytosis, Epstein-Barr virus infection, Graft-versus-host disease, Hematopoietic cell lineage, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Inflammatory bowel disease, Influenza A, Intestinal immune network for IgA production, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Natural killer cell mediated cytotoxicity, Phagosome, Rheumatoid arthritis, Staphylococcus aureus infection, Systemic lupus erythematosus, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Viral carcinogenesis, Viral myocarditis 💬 | 1件: 13 13 |
321 | GLATIRAMER ACETATO | 1件: Glatiramer Glatiramer | 1件: D04318
D04318
| 20件: HLA-A HLA-A, HLA-B, HLA-C, HLA-DMA, HLA-DMB, HLA-DOA, HLA-DOB, HLA-DPA1, HLA-DPB1, HLA-DQA1, HLA-DQA2, HLA-DQB1, HLA-DRA, HLA-DRB1, HLA-DRB3, HLA-DRB4, HLA-DRB5, HLA-E, HLA-F, HLA-G 💬 | 32件: Allograft rejection Allograft rejection, Antigen processing and presentation, Asthma, Autoimmune thyroid disease, Cell adhesion molecules, Cellular senescence, Endocytosis, Epstein-Barr virus infection, Graft-versus-host disease, Hematopoietic cell lineage, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Inflammatory bowel disease, Influenza A, Intestinal immune network for IgA production, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Natural killer cell mediated cytotoxicity, Phagosome, Rheumatoid arthritis, Staphylococcus aureus infection, Systemic lupus erythematosus, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Viral carcinogenesis, Viral myocarditis 💬 | 1件: 13 13 |
322 | GLATIRAMERO ACETATO | - | - | - | - | 1件: 13 13 |
323 | Gleevec | - | - | - | - | 1件: 34 34 |
324 | Glentek 50 mg compresse rivestite con film | - | - | - | - | 1件: 18 18 |
325 | Glentek 50 mg film-coated tablets | - | - | - | - | 1件: 18 18 |
326 | Glial cell line-derived neurotrophic factor | - | - | - | - | 1件: 6 6 |
327 | Glial Cell Line-Derived Neurotrophic Factor (GDNF) | - | - | - | - | 1件: 6 6 |
328 | Glicerol-1,3-didecanoato-2-octadeca-(6Z,9Z,12Z)-trienoato | - | - | - | - | 1件: 13 13 |
329 | Gliolan | 1件: Aminolevulinic acid Aminolevulinic acid | 2件: D02908
D02908
,
D07567
| - | - | 1件: 97 97 |
330 | GLIVEC | 1件: Imatinib Imatinib | 2件: D01441
D01441
,
D08066
| 3件: ABL1 ABL1, KIT, PDGFRA 💬 | 32件: Acute myeloid leukemia Acute myeloid leukemia, Axon guidance, Breast cancer, Calcium signaling pathway, Cell cycle, Central carbon metabolism in cancer, Chemical carcinogenesis - reactive oxygen species, Choline metabolism in cancer, Chronic myeloid leukemia, EGFR tyrosine kinase inhibitor resistance, Endocytosis, ErbB signaling pathway, Focal adhesion, Gap junction, Glioma, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, MAPK signaling pathway, Melanogenesis, Melanoma, MicroRNAs in cancer, Neurotrophin signaling pathway, PI3K-Akt signaling pathway, Pathogenic Escherichia coli infection, Pathways in cancer, Phospholipase D signaling pathway, Prostate cancer, Rap1 signaling pathway, Ras signaling pathway, Regulation of actin cytoskeleton, Viral myocarditis 💬 | 2件: 51 51, 86 |
331 | GLIVEC 100 mg comprimidos recubiertos con película | 1件: Imatinib Imatinib | 2件: D01441
D01441
,
D08066
| 3件: ABL1 ABL1, KIT, PDGFRA 💬 | 32件: Acute myeloid leukemia Acute myeloid leukemia, Axon guidance, Breast cancer, Calcium signaling pathway, Cell cycle, Central carbon metabolism in cancer, Chemical carcinogenesis - reactive oxygen species, Choline metabolism in cancer, Chronic myeloid leukemia, EGFR tyrosine kinase inhibitor resistance, Endocytosis, ErbB signaling pathway, Focal adhesion, Gap junction, Glioma, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, MAPK signaling pathway, Melanogenesis, Melanoma, MicroRNAs in cancer, Neurotrophin signaling pathway, PI3K-Akt signaling pathway, Pathogenic Escherichia coli infection, Pathways in cancer, Phospholipase D signaling pathway, Prostate cancer, Rap1 signaling pathway, Ras signaling pathway, Regulation of actin cytoskeleton, Viral myocarditis 💬 | 2件: 34 34, 86 |
332 | Glivec 100 mg Filmtabletten | 1件: Imatinib Imatinib | 2件: D01441
D01441
,
D08066
| 3件: ABL1 ABL1, KIT, PDGFRA 💬 | 32件: Acute myeloid leukemia Acute myeloid leukemia, Axon guidance, Breast cancer, Calcium signaling pathway, Cell cycle, Central carbon metabolism in cancer, Chemical carcinogenesis - reactive oxygen species, Choline metabolism in cancer, Chronic myeloid leukemia, EGFR tyrosine kinase inhibitor resistance, Endocytosis, ErbB signaling pathway, Focal adhesion, Gap junction, Glioma, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, MAPK signaling pathway, Melanogenesis, Melanoma, MicroRNAs in cancer, Neurotrophin signaling pathway, PI3K-Akt signaling pathway, Pathogenic Escherichia coli infection, Pathways in cancer, Phospholipase D signaling pathway, Prostate cancer, Rap1 signaling pathway, Ras signaling pathway, Regulation of actin cytoskeleton, Viral myocarditis 💬 | 2件: 51 51, 86 |
333 | Glivec 100 mg Hartkapsel | 1件: Imatinib Imatinib | 2件: D01441
D01441
,
D08066
| 3件: ABL1 ABL1, KIT, PDGFRA 💬 | 32件: Acute myeloid leukemia Acute myeloid leukemia, Axon guidance, Breast cancer, Calcium signaling pathway, Cell cycle, Central carbon metabolism in cancer, Chemical carcinogenesis - reactive oxygen species, Choline metabolism in cancer, Chronic myeloid leukemia, EGFR tyrosine kinase inhibitor resistance, Endocytosis, ErbB signaling pathway, Focal adhesion, Gap junction, Glioma, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, MAPK signaling pathway, Melanogenesis, Melanoma, MicroRNAs in cancer, Neurotrophin signaling pathway, PI3K-Akt signaling pathway, Pathogenic Escherichia coli infection, Pathways in cancer, Phospholipase D signaling pathway, Prostate cancer, Rap1 signaling pathway, Ras signaling pathway, Regulation of actin cytoskeleton, Viral myocarditis 💬 | 1件: 86 86 |
334 | GLIVEC 400 mg comprimidos recubiertos con película | 1件: Imatinib Imatinib | 2件: D01441
D01441
,
D08066
| 3件: ABL1 ABL1, KIT, PDGFRA 💬 | 32件: Acute myeloid leukemia Acute myeloid leukemia, Axon guidance, Breast cancer, Calcium signaling pathway, Cell cycle, Central carbon metabolism in cancer, Chemical carcinogenesis - reactive oxygen species, Choline metabolism in cancer, Chronic myeloid leukemia, EGFR tyrosine kinase inhibitor resistance, Endocytosis, ErbB signaling pathway, Focal adhesion, Gap junction, Glioma, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, MAPK signaling pathway, Melanogenesis, Melanoma, MicroRNAs in cancer, Neurotrophin signaling pathway, PI3K-Akt signaling pathway, Pathogenic Escherichia coli infection, Pathways in cancer, Phospholipase D signaling pathway, Prostate cancer, Rap1 signaling pathway, Ras signaling pathway, Regulation of actin cytoskeleton, Viral myocarditis 💬 | 1件: 34 34 |
335 | Glivec® | 1件: Imatinib Imatinib | 2件: D01441
D01441
,
D08066
| 3件: ABL1 ABL1, KIT, PDGFRA 💬 | 32件: Acute myeloid leukemia Acute myeloid leukemia, Axon guidance, Breast cancer, Calcium signaling pathway, Cell cycle, Central carbon metabolism in cancer, Chemical carcinogenesis - reactive oxygen species, Choline metabolism in cancer, Chronic myeloid leukemia, EGFR tyrosine kinase inhibitor resistance, Endocytosis, ErbB signaling pathway, Focal adhesion, Gap junction, Glioma, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, MAPK signaling pathway, Melanogenesis, Melanoma, MicroRNAs in cancer, Neurotrophin signaling pathway, PI3K-Akt signaling pathway, Pathogenic Escherichia coli infection, Pathways in cancer, Phospholipase D signaling pathway, Prostate cancer, Rap1 signaling pathway, Ras signaling pathway, Regulation of actin cytoskeleton, Viral myocarditis 💬 | 1件: 86 86 |
336 | Glivec® 100 mg Filmtabletten | 1件: Imatinib Imatinib | 2件: D01441
D01441
,
D08066
| 3件: ABL1 ABL1, KIT, PDGFRA 💬 | 32件: Acute myeloid leukemia Acute myeloid leukemia, Axon guidance, Breast cancer, Calcium signaling pathway, Cell cycle, Central carbon metabolism in cancer, Chemical carcinogenesis - reactive oxygen species, Choline metabolism in cancer, Chronic myeloid leukemia, EGFR tyrosine kinase inhibitor resistance, Endocytosis, ErbB signaling pathway, Focal adhesion, Gap junction, Glioma, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, MAPK signaling pathway, Melanogenesis, Melanoma, MicroRNAs in cancer, Neurotrophin signaling pathway, PI3K-Akt signaling pathway, Pathogenic Escherichia coli infection, Pathways in cancer, Phospholipase D signaling pathway, Prostate cancer, Rap1 signaling pathway, Ras signaling pathway, Regulation of actin cytoskeleton, Viral myocarditis 💬 | 1件: 86 86 |
337 | GLP-1 | - | - | - | - | 1件: 299 299 |
338 | GLPG0259 | - | - | - | - | 1件: 46 46 |
339 | GLPG0259 (Part B) | - | - | - | - | 1件: 46 46 |
340 | GLPG0259 oral capsule | - | - | - | - | 1件: 46 46 |
341 | GLPG0634 | - | - | - | - | 3件: 46 46, 96, 271 |
342 | GLPG0974 | - | - | - | - | 1件: 97 97 |
343 | GLPG1205 | - | - | - | - | 3件: 85 85, 96, 97 |
344 | GLPG1690 | - | - | - | - | 2件: 51 51, 85 |
345 | GLPG1690 600 mg QD | - | - | - | - | 1件: 85 85 |
346 | GLPG1837 | - | - | - | - | 1件: 299 299 |
347 | GLPG1837 dose 1 | - | - | - | - | 1件: 299 299 |
348 | GLPG1837 dose 2 | - | - | - | - | 1件: 299 299 |
349 | GLPG1837 dose 3 | - | - | - | - | 1件: 299 299 |
350 | GLPG2222 | - | - | - | - | 1件: 299 299 |
351 | GLPG2222 100 mg | - | - | - | - | 1件: 299 299 |
352 | GLPG2222 150 mg q.d. | - | - | - | - | 1件: 299 299 |
353 | GLPG2222 200 mg | - | - | - | - | 1件: 299 299 |
354 | GLPG2222 300 mg q.d. | - | - | - | - | 1件: 299 299 |
355 | GLPG2222 400 mg | - | - | - | - | 1件: 299 299 |
356 | GLPG2222 50 mg | - | - | - | - | 1件: 299 299 |
357 | GLPG2451 dose regimen A | - | - | - | - | 1件: 299 299 |
358 | GLPG2451 dose regimen B | - | - | - | - | 1件: 299 299 |
359 | GLPG2737 | - | - | - | - | 2件: 67 67, 299 |
360 | GLPG2737 single dose | - | - | - | - | 1件: 299 299 |
361 | GLPG3067 | - | - | - | - | 1件: 299 299 |
362 | GLPG3067 single dose | - | - | - | - | 1件: 299 299 |
363 | GLPG3970 | - | - | - | - | 3件: 46 46, 53, 97 |
364 | GLPG3970 film-coated tablet | - | - | - | - | 1件: 49 49 |
365 | Glucagon | 1件: Glucagon Glucagon | 2件: D00116
D00116
,
D02118
| 1件: GCGR GCGR 💬 | 2件: Glucagon signaling pathway Glucagon signaling pathway, Neuroactive ligand-receptor interaction 💬 | 1件: 78 78 |
366 | Glucagon stimulation test and insulin tolerance test | 1件: Glucagon Glucagon | 2件: D00116
D00116
,
D02118
| 1件: GCGR GCGR 💬 | 2件: Glucagon signaling pathway Glucagon signaling pathway, Neuroactive ligand-receptor interaction 💬 | 1件: 78 78 |
367 | GLUCOCEREBROSIDASE | - | - | - | - | 1件: 19 19 |
368 | GLUCOCEREBROSIDASE UMANO GENE-ATTIVATO | - | - | - | - | 1件: 19 19 |
369 | GlucoCorticoid | - | - | - | - | 2件: 46 46, 228 |
370 | Glucocorticoid (GC) | - | - | - | - | 2件: 43 43, 44 |
371 | Glucocorticoid (prednisone or prednisolone) | 2件: Prednisolone Prednisolone, Prednisone | 9件: D00472
D00472
,
D00473
,
D00980
,
D00981
,
D00982
,
D01239
,
D01998
,
D02156
,
D03301
| 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 84 84 |
372 | Glucocorticoid Agent | - | - | - | - | 1件: 46 46 |
373 | Glucocorticoid Treatment | - | - | - | - | 1件: 41 41 |
374 | Glucocorticoids | - | - | - | - | 8件: 40 40, 41, 43, 44, 60, 62, 75, 300 |
375 | Glucocorticoids (GC) | - | - | - | - | 2件: 43 43, 44 |
376 | Glucocorticoids (permitted,not necessary) | - | - | - | - | 1件: 46 46 |
377 | Glucocorticoids - Reduced Dose | - | - | - | - | 2件: 43 43, 44 |
378 | Glucocorticoids - Standard Dose | - | - | - | - | 2件: 43 43, 44 |
379 | Glucocorticoids [Reduced Dose] | - | - | - | - | 2件: 43 43, 44 |
380 | Glucocorticoids [Standard Dose] | - | - | - | - | 2件: 43 43, 44 |
381 | Glucophage (metformin) | 1件: Metformin Metformin | 2件: D00944
D00944
,
D04966
| 2件: PRKAA1 PRKAA1, PRKAA2 💬 | 20件: AMPK signaling pathway AMPK signaling pathway, Adipocytokine signaling pathway, Alcoholic liver disease, Apelin signaling pathway, Autophagy - animal, Circadian rhythm, Fluid shear stress and atherosclerosis, FoxO signaling pathway, Glucagon signaling pathway, Hypertrophic cardiomyopathy, Insulin resistance, Insulin signaling pathway, Longevity regulating pathway, Longevity regulating pathway - multiple species, Non-alcoholic fatty liver disease, Oxytocin signaling pathway, PI3K-Akt signaling pathway, Thermogenesis, Tight junction, mTOR signaling pathway 💬 | 2件: 46 46, 75 |
382 | Glucorticoid Taper Regimen | - | - | - | - | 1件: 40 40 |
383 | Glucosamine | 1件: Glucosamine Glucosamine | 1件: D04334
D04334
| - | - | 2件: 46 46, 271 |
384 | Glucose | 1件: Dextrose, unspecified form Dextrose, unspecified form | - | - | - | 15件: 2 2, 6, 13, 49, 50, 65, 75, 86, 88, 96, 160, 195, 254, 257, 299 |
385 | Glucose intake | 1件: Dextrose, unspecified form Dextrose, unspecified form | - | - | - | 1件: 257 257 |
386 | Glucose Tablet | 1件: Dextrose, unspecified form Dextrose, unspecified form | - | - | - | 1件: 50 50 |
387 | Glucosidase alfa | - | - | - | - | 1件: 256 256 |
388 | GLUT1 DS | - | - | - | - | 1件: 248 248 |
389 | Glutamate and aspartate | - | - | - | - | 1件: 13 13 |
390 | Glutamine | 1件: L-Glutamine L-Glutamine | 1件: D00015
D00015
| - | - | 7件: 87 87, 89, 96, 97, 113, 245, 299 |
391 | Glutathione | 1件: Glutathione Glutathione | 2件: D00014
D00014
,
D00031
| - | - | 2件: 6 6, 299 |
392 | GLUTATHIONE SODIUM | 1件: Glutathione Glutathione | 2件: D00014
D00014
,
D00031
| - | - | 1件: 299 299 |
393 | Gluten-free diet | - | - | - | - | 1件: 94 94 |
394 | GLWL-01 | - | - | - | - | 1件: 193 193 |
395 | Glycerine | 1件: Glycerin Glycerin | 1件: D00028
D00028
| - | - | 1件: 265 265 |
396 | Glycerol | 1件: Glycerin Glycerin | 1件: D00028
D00028
| - | - | 5件: 6 6, 13, 79, 316, 317 |
397 | Glycerol Phenylbutyrate | 3件: Glycerin Glycerin, Glycerol phenylbutyrate, Phenylbutyric acid | 2件: D00028
D00028
,
D10127
| - | - | 1件: 6 6 |
398 | Glycerol-1,3-didecanoate-2-octadeca-(6Z,9Z,12Z)-trienoate | 1件: Glycerin Glycerin | 1件: D00028
D00028
| - | - | 1件: 13 13 |
399 | Glycerol/Saline | 1件: Glycerin Glycerin | 1件: D00028
D00028
| - | - | 2件: 316 316, 317 |
400 | Glyceryl tri-(4-phenylbutyrate) | 1件: Phenylbutyric acid Phenylbutyric acid | - | - | - | 1件: 251 251 |
401 | Glyceryl tri-(4-phenylbutyrate)(GT4P) | 2件: Glycerol phenylbutyrate Glycerol phenylbutyrate, Phenylbutyric acid | 1件: D10127
D10127
| - | - | 1件: 251 251 |
402 | Glyceryl triacetate | 1件: Triacetin Triacetin | 1件: D00384
D00384
| - | - | 1件: 307 307 |
403 | Glyceryl Trierucate | 1件: Glyceryl Trierucate Glyceryl Trierucate | - | - | - | 1件: 20 20 |
404 | Glyceryl trierucate/glyceryl trioleate | 2件: Glyceryl Trierucate Glyceryl Trierucate, Glyceryl Trioleate | - | - | - | 1件: 20 20 |
405 | Glyceryl Trioleate | 1件: Glyceryl Trioleate Glyceryl Trioleate | - | - | - | 1件: 20 20 |
406 | GLYCINE | 1件: Glycine Glycine | 1件: D00011
D00011
| - | - | 5件: 35 35, 60, 86, 226, 299 |
407 | Glycine Buffer | 1件: Glycine Glycine | 1件: D00011
D00011
| - | - | 1件: 299 299 |
408 | Glycolic acid | 1件: Glycolic acid Glycolic acid | - | - | - | 1件: 65 65 |
409 | Glycomacropeptide-based protein substitute | - | - | - | - | 1件: 240 240 |
410 | Glycopyrrolate | - | - | - | - | 2件: 6 6, 34 |
411 | Glycosade | - | - | - | - | 3件: 65 65, 256, 257 |
412 | GlycosBio Nutritional Supplement | - | - | - | - | 1件: 299 299 |
413 | Glycosides Of Tripterygium Wilfordii Hook(GTW) | 1件: Tripterygium wilfordii whole Tripterygium wilfordii whole | - | - | - | 1件: 224 224 |
414 | Glycyrrhetinic Acid | - | - | - | - | 1件: 63 63 |
415 | Glycyrrhiza | 1件: Glycyrrhiza glabra Glycyrrhiza glabra | - | - | - | 2件: 53 53, 97 |
416 | Glycyrrhiza glabra | 1件: Glycyrrhiza glabra Glycyrrhiza glabra | - | - | - | 1件: 97 97 |
417 | GLYCYRRHIZA GLABRA ROOT | 1件: Glycyrrhiza glabra Glycyrrhiza glabra | - | - | - | 1件: 97 97 |
418 | Glycyrrhizin | 1件: Glycyrrhizic acid Glycyrrhizic acid | 1件: D00157
D00157
| - | - | 1件: 51 51 |
419 | GLYPRESSINE 1 mg/5 mL, poudre et solvant pour solution injectable (I.V.) | - | - | - | - | 1件: 299 299 |
420 | GM-CSF | - | - | - | - | 3件: 51 51, 60, 229 |
421 | GM-CSF (granulocyte-macrophage colony-stimulating factor, sargramostim) | 1件: Sargramostim Sargramostim | 1件: D05803
D05803
| 1件: CSF2RA CSF2RA 💬 | 4件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Hematopoietic cell lineage, JAK-STAT signaling pathway, Pathways in cancer 💬 | 1件: 229 229 |
422 | GM-CSF [Leukine (Sargramostim)] | 1件: Sargramostim Sargramostim | 1件: D05803
D05803
| 1件: CSF2RA CSF2RA 💬 | 4件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Hematopoietic cell lineage, JAK-STAT signaling pathway, Pathways in cancer 💬 | 1件: 229 229 |
423 | GM-CSF inhalation therapy | - | - | - | - | 1件: 229 229 |
424 | GM-CSF, fosfomycin and metronidazole | 2件: Fosfomycin Fosfomycin, Metronidazole | 7件: D00409
D00409
,
D00925
,
D02187
,
D02188
,
D04253
,
D05016
,
D05017
| - | - | 1件: 97 97 |
425 | GM1 ganglioside | - | - | - | - | 1件: 6 6 |
426 | GM604 | - | - | - | - | 1件: 2 2 |
427 | GM608 | - | - | - | - | 1件: 6 6 |
428 | GMA161 | - | - | - | - | 1件: 63 63 |
429 | GMA301 Injection | - | - | - | - | 1件: 86 86 |
430 | GNbAC1 | - | - | - | - | 1件: 13 13 |
431 | GNbAC1 Monoclonal Antibody | - | - | - | - | 1件: 13 13 |
432 | GNR-055 | - | - | - | - | 1件: 19 19 |
433 | GNR-069 | - | - | - | - | 1件: 63 63 |
434 | GnRH | 1件: Gonadorelin Gonadorelin | 4件: D00988
D00988
,
D03267
,
D04361
,
D08027
| 1件: GNRHR GNRHR 💬 | 2件: GnRH signaling pathway GnRH signaling pathway, Neuroactive ligand-receptor interaction 💬 | 1件: 76 76 |
435 | GnRH agonist | 1件: Gonadorelin Gonadorelin | 4件: D00988
D00988
,
D03267
,
D04361
,
D08027
| 1件: GNRHR GNRHR 💬 | 2件: GnRH signaling pathway GnRH signaling pathway, Neuroactive ligand-receptor interaction 💬 | 1件: 76 76 |
436 | GNT0004 | - | - | - | - | 1件: 113 113 |
437 | GNT0006 | - | - | - | - | 1件: 113 113 |
438 | GOCOVRI | - | - | - | - | 1件: 6 6 |
439 | GOL | - | - | - | - | 1件: 46 46 |
440 | Gold | 1件: Gold Gold | - | - | - | 43件: 2 2, 5, 6, 13, 17, 34, 35, 46, 49, 50, 53, 58, 65, 68, 76, 84, 86, 91, 93, 95, 96, 97, 98, 113, 137, 158, 162, 171, 193, 218, 222, 224, 227, 230, 235, 271, 291, 294, 296, 298, 299, 310, 318 |
441 | Gold Nanocrystals | - | - | - | - | 3件: 2 2, 6, 13 |
442 | Gold standard of visual identification and evaluation of viability of the parathyroid glands. | 1件: Gold Gold | - | - | - | 1件: 235 235 |
443 | GOLIMUMAB | 1件: Golimumab Golimumab | 1件: D04358
D04358
| 1件: TNF TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 8件: 46 46, 56, 84, 96, 97, 107, 270, 271 |
444 | Golimumab (CNTO 148) | 1件: Golimumab Golimumab | 1件: D04358
D04358
| 1件: TNF TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 1件: 271 271 |
445 | Golimumab (GLM) | 1件: Golimumab Golimumab | 1件: D04358
D04358
| 1件: TNF TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 1件: 97 97 |
446 | Golimumab (GOL) | 1件: Golimumab Golimumab | 1件: D04358
D04358
| 1件: TNF TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 1件: 56 56 |
447 | Golimumab (Optimization) | 1件: Golimumab Golimumab | 1件: D04358
D04358
| 1件: TNF TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 1件: 97 97 |
448 | Golimumab 1 mg per kg | 1件: Golimumab Golimumab | 1件: D04358
D04358
| 1件: TNF TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 1件: 97 97 |
449 | Golimumab 100 mg | 1件: Golimumab Golimumab | 1件: D04358
D04358
| 1件: TNF TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 2件: 46 46, 97 |
450 | Golimumab 100 mg injections | 1件: Golimumab Golimumab | 1件: D04358
D04358
| 1件: TNF TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 1件: 46 46 |
451 | Golimumab 2 mg per kg | 1件: Golimumab Golimumab | 1件: D04358
D04358
| 1件: TNF TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 1件: 97 97 |
452 | Golimumab 2 mg/kg IV | 1件: Golimumab Golimumab | 1件: D04358
D04358
| 1件: TNF TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 1件: 46 46 |
453 | Golimumab 200 mg | 1件: Golimumab Golimumab | 1件: D04358
D04358
| 1件: TNF TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 1件: 97 97 |
454 | Golimumab 4 mg per kg | 1件: Golimumab Golimumab | 1件: D04358
D04358
| 1件: TNF TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 1件: 97 97 |
455 | Golimumab 400 mg | 1件: Golimumab Golimumab | 1件: D04358
D04358
| 1件: TNF TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 1件: 97 97 |
456 | Golimumab 50 mg | 1件: Golimumab Golimumab | 1件: D04358
D04358
| 1件: TNF TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 2件: 46 46, 97 |
457 | Golimumab 50 mg in patients <80 kg and Golimumab 100 mg in patients >80 kg | 1件: Golimumab Golimumab | 1件: D04358
D04358
| 1件: TNF TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 1件: 97 97 |
458 | Golimumab 50 mg injections | 1件: Golimumab Golimumab | 1件: D04358
D04358
| 1件: TNF TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 1件: 46 46 |
459 | Golimumab 50 mg SC | 1件: Golimumab Golimumab | 1件: D04358
D04358
| 1件: TNF TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 1件: 46 46 |
460 | Golimumab Dose 1 | 1件: Golimumab Golimumab | 1件: D04358
D04358
| 1件: TNF TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 1件: 97 97 |
461 | Golimumab Dose 2 | 1件: Golimumab Golimumab | 1件: D04358
D04358
| 1件: TNF TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 1件: 97 97 |
462 | Golimumab Final Vialed Product (FVP) | 1件: Golimumab Golimumab | 1件: D04358
D04358
| 1件: TNF TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 1件: 46 46 |
463 | Golimumab Injection | 1件: Golimumab Golimumab | 1件: D04358
D04358
| 1件: TNF TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 1件: 271 271 |
464 | Golimumab Intravenous | 1件: Golimumab Golimumab | 1件: D04358
D04358
| 1件: TNF TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 1件: 46 46 |
465 | Golimumab Intravenous (IV) | 1件: Golimumab Golimumab | 1件: D04358
D04358
| 1件: TNF TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 1件: 46 46 |
466 | Golimumab liquid in prefilled pen | 1件: Golimumab Golimumab | 1件: D04358
D04358
| 1件: TNF TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 1件: 46 46 |
467 | Golimumab liquid in prefilled pen or Prefilled Syringe | 1件: Golimumab Golimumab | 1件: D04358
D04358
| 1件: TNF TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 1件: 46 46 |
468 | Golimumab Liquid in prefilled syringe | 1件: Golimumab Golimumab | 1件: D04358
D04358
| 1件: TNF TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 4件: 46 46, 84, 97, 107 |
469 | Golimumab Liquid in Vial | 1件: Golimumab Golimumab | 1件: D04358
D04358
| 1件: TNF TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 3件: 46 46, 97, 271 |
470 | Golimumab Pre-Filled Syringe | 1件: Golimumab Golimumab | 1件: D04358
D04358
| 1件: TNF TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 2件: 46 46, 271 |
471 | Golimumab prefilled pen | 1件: Golimumab Golimumab | 1件: D04358
D04358
| 1件: TNF TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 1件: 46 46 |
472 | Golimumab prefilled pen or prefilled syringe | 1件: Golimumab Golimumab | 1件: D04358
D04358
| 1件: TNF TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 1件: 46 46 |
473 | Golimumab Prefilled Syringe | 1件: Golimumab Golimumab | 1件: D04358
D04358
| 1件: TNF TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 1件: 97 97 |
474 | Golimumab treatment optimization. | 1件: Golimumab Golimumab | 1件: D04358
D04358
| 1件: TNF TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 1件: 97 97 |
475 | GOLODIRSEN | 1件: Golodirsen Golodirsen | 1件: D11707
D11707
| 1件: DMD DMD 💬 | 4件: Arrhythmogenic right ventricular cardiomyopathy Arrhythmogenic right ventricular cardiomyopathy, Dilated cardiomyopathy, Hypertrophic cardiomyopathy, Viral myocarditis 💬 | 1件: 113 113 |
476 | Golodirsen 50 MG/1 ML Intravenous Solution [VYONDYS 53] | 1件: Golodirsen Golodirsen | 1件: D11707
D11707
| 1件: DMD DMD 💬 | 4件: Arrhythmogenic right ventricular cardiomyopathy Arrhythmogenic right ventricular cardiomyopathy, Dilated cardiomyopathy, Hypertrophic cardiomyopathy, Viral myocarditis 💬 | 1件: 113 113 |
477 | Gonadorelin | 1件: Gonadorelin Gonadorelin | 4件: D00988
D00988
,
D03267
,
D04361
,
D08027
| 1件: GNRHR GNRHR 💬 | 2件: GnRH signaling pathway GnRH signaling pathway, Neuroactive ligand-receptor interaction 💬 | 1件: 76 76 |
478 | Goserelin | 1件: Goserelin Goserelin | 2件: D00573
D00573
,
D04405
| 1件: GNRHR GNRHR 💬 | 2件: GnRH signaling pathway GnRH signaling pathway, Neuroactive ligand-receptor interaction 💬 | 1件: 1 1 |
479 | GP2013 | - | - | - | - | 1件: 46 46 |
480 | GP2013 - A Proposed biosimilar rituximab | 1件: Rituximab Rituximab | 1件: D02994
D02994
| 1件: MS4A1 MS4A1 💬 | 1件: Hematopoietic cell lineage Hematopoietic cell lineage 💬 | 1件: 46 46 |
481 | GP2015 | - | - | - | - | 1件: 46 46 |
482 | GP2017 | - | - | - | - | 2件: 46 46, 271 |
483 | GP2017 (adalimumab biosimilar) | 1件: Adalimumab Adalimumab | 1件: D02597
D02597
| 1件: TNF TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 1件: 271 271 |
484 | Gp91 Grans | - | - | - | - | 1件: 65 65 |
485 | GPI 1485 | - | - | - | - | 1件: 6 6 |
486 | GR181413 | - | - | - | - | 1件: 19 19 |
487 | GR181413A | - | - | - | - | 1件: 19 19 |
488 | GR181413A/AT1001 capsule | - | - | - | - | 1件: 19 19 |
489 | GR181413A/AT1001 solution | - | - | - | - | 1件: 19 19 |
490 | Gradient | - | - | - | - | 4件: 58 58, 86, 149, 215 |
491 | Graft intracerebral of foetal neurons | - | - | - | - | 1件: 8 8 |
492 | Graft-versus-tumor induction therapy | - | - | - | - | 2件: 60 60, 285 |
493 | Gralise | - | - | - | - | 2件: 97 97, 226 |
494 | Gran | - | - | - | - | 1件: 51 51 |
495 | Granocyte | - | - | - | - | 2件: 18 18, 57 |
496 | GRANOCYTE - 34 million IU (Lenograstim rHuG-CSF) | 1件: Lenograstim Lenograstim | 1件: D03247
D03247
| 1件: CSF3R CSF3R 💬 | 5件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Hematopoietic cell lineage, JAK-STAT signaling pathway, PI3K-Akt signaling pathway, Pathways in cancer 💬 | 1件: 57 57 |
497 | Granocyte Lenograstim | 1件: Lenograstim Lenograstim | 1件: D03247
D03247
| 1件: CSF3R CSF3R 💬 | 5件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Hematopoietic cell lineage, JAK-STAT signaling pathway, PI3K-Akt signaling pathway, Pathways in cancer 💬 | 1件: 57 57 |
498 | Granulated mesalamine | 1件: Mesalazine Mesalazine | 1件: D00377
D00377
| - | - | 1件: 97 97 |
499 | Granulocyte - colony stimulating factor (G-CSF) | 1件: Filgrastim Filgrastim | 1件: D03235
D03235
| 1件: CSF3R CSF3R 💬 | 5件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Hematopoietic cell lineage, JAK-STAT signaling pathway, PI3K-Akt signaling pathway, Pathways in cancer 💬 | 1件: 2 2 |
500 | Granulocyte Colony Stimulating Factor | 1件: Filgrastim Filgrastim | 1件: D03235
D03235
| 1件: CSF3R CSF3R 💬 | 5件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Hematopoietic cell lineage, JAK-STAT signaling pathway, PI3K-Akt signaling pathway, Pathways in cancer 💬 | 6件: 2 2, 28, 36, 57, 65, 85 |
501 | Granulocyte colony stimulating factor (G-CSF) | 1件: Filgrastim Filgrastim | 1件: D03235
D03235
| 1件: CSF3R CSF3R 💬 | 5件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Hematopoietic cell lineage, JAK-STAT signaling pathway, PI3K-Akt signaling pathway, Pathways in cancer 💬 | 1件: 65 65 |
502 | Granulocyte Colony Stimulating Factor (GCSF) | 1件: Filgrastim Filgrastim | 1件: D03235
D03235
| 1件: CSF3R CSF3R 💬 | 5件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Hematopoietic cell lineage, JAK-STAT signaling pathway, PI3K-Akt signaling pathway, Pathways in cancer 💬 | 2件: 36 36, 57 |
503 | Granulocyte Colony-Stimulating Factor | - | - | - | - | 1件: 296 296 |
504 | Granulocyte colony-stimulating factor (Filgrastim) | 1件: Filgrastim Filgrastim | 1件: D03235
D03235
| 1件: CSF3R CSF3R 💬 | 5件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Hematopoietic cell lineage, JAK-STAT signaling pathway, PI3K-Akt signaling pathway, Pathways in cancer 💬 | 1件: 113 113 |
505 | Granulocyte-colony stimulating factor (G-CSF) and prednisone | 2件: Filgrastim Filgrastim, Prednisone | 2件: D00473
D00473
,
D03235
| 2件: CSF3R CSF3R, NR3C1 💬 | 6件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Hematopoietic cell lineage, JAK-STAT signaling pathway, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, Pathways in cancer 💬 | 1件: 13 13 |
506 | Granulocyte-macrophage colony stimulating factor (GM-CSF) | - | - | - | - | 1件: 229 229 |
507 | Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) | - | - | - | - | 1件: 11 11 |
508 | Grapefruit | 1件: Grapefruit Grapefruit | - | - | - | 5件: 6 6, 46, 50, 83, 97 |
509 | Grapefruit Juice | 1件: Grapefruit Grapefruit | - | - | - | 1件: 83 83 |
510 | GRC 4039 | - | - | - | - | 1件: 46 46 |
511 | Green Tea | 1件: Green tea leaf Green tea leaf | 1件: D06903
D06903
| - | - | 5件: 6 6, 17, 28, 46, 96 |
512 | Green Tea Extract | 1件: Green tea leaf Green tea leaf | 1件: D06903
D06903
| - | - | 1件: 28 28 |
513 | Green tea group | 1件: Green tea leaf Green tea leaf | 1件: D06903
D06903
| - | - | 1件: 46 46 |
514 | GREEN TEA LEAF | 2件: Green tea leaf Green tea leaf, Tea leaf | 1件: D06903
D06903
| - | - | 1件: 17 17 |
515 | Green Tea Polyphenols (EGCG/ECG) | 2件: Epigallocatechin gallate Epigallocatechin gallate, Green tea leaf | 1件: D06903
D06903
| - | - | 1件: 6 6 |
516 | GRF6021 | - | - | - | - | 1件: 6 6 |
517 | Group 1 or Orencia treated group | 1件: Abatacept Abatacept | 1件: D03203
D03203
| 2件: CD80 CD80, CD86 💬 | 12件: Allograft rejection Allograft rejection, Autoimmune thyroid disease, Cell adhesion molecules, Graft-versus-host disease, Intestinal immune network for IgA production, Kaposi sarcoma-associated herpesvirus infection, Rheumatoid arthritis, Systemic lupus erythematosus, Toll-like receptor signaling pathway, Transcriptional misregulation in cancer, Type I diabetes mellitus, Viral myocarditis 💬 | 1件: 46 46 |
518 | Group 1- Control Diet | - | - | - | - | 1件: 97 97 |
519 | Group 2 ustekinumab 130 mg | 1件: Ustekinumab Ustekinumab | 1件: D09214
D09214
| 3件: IL12A IL12A, IL12B, IL23A 💬 | 28件: African trypanosomiasis African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Amoebiasis, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Herpes simplex virus 1 infection, Inflammatory bowel disease, Influenza A, JAK-STAT signaling pathway, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, Malaria, Measles, Pathways in cancer, Pertussis, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus 💬 | 1件: 96 96 |
520 | Group 2- UCD Diet | - | - | - | - | 1件: 97 97 |
521 | Group 3: ustekinumab approximately 6 mg/kg | 1件: Ustekinumab Ustekinumab | 1件: D09214
D09214
| 3件: IL12A IL12A, IL12B, IL23A 💬 | 28件: African trypanosomiasis African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Amoebiasis, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Herpes simplex virus 1 infection, Inflammatory bowel disease, Influenza A, JAK-STAT signaling pathway, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, Malaria, Measles, Pathways in cancer, Pertussis, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus 💬 | 1件: 96 96 |
522 | Group A SLE prospective study | - | - | - | - | 1件: 49 49 |
523 | Group AD Anti-PD + Antidepressant | - | - | - | - | 1件: 6 6 |
524 | Group C meningococcal conjugate vaccine | - | - | - | - | 1件: 14 14 |
525 | Group R Rasagiline | 1件: Rasagiline Rasagiline | 3件: D02562
D02562
,
D08469
,
D10829
| 1件: MAOB MAOB 💬 | 14件: Alcoholism Alcoholism, Amphetamine addiction, Arginine and proline metabolism, Cocaine addiction, Dopaminergic synapse, Drug metabolism - cytochrome P450, Glycine, serine and threonine metabolism, Histidine metabolism, Metabolic pathways, Parkinson disease, Phenylalanine metabolism, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism 💬 | 1件: 6 6 |
526 | Group R+AD Rasagiline + Antidepressant | 1件: Rasagiline Rasagiline | 3件: D02562
D02562
,
D08469
,
D10829
| 1件: MAOB MAOB 💬 | 14件: Alcoholism Alcoholism, Amphetamine addiction, Arginine and proline metabolism, Cocaine addiction, Dopaminergic synapse, Drug metabolism - cytochrome P450, Glycine, serine and threonine metabolism, Histidine metabolism, Metabolic pathways, Parkinson disease, Phenylalanine metabolism, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism 💬 | 1件: 6 6 |
527 | Growth colony stimulating factor (G-CSF) | 1件: Filgrastim Filgrastim | 1件: D03235
D03235
| 1件: CSF3R CSF3R 💬 | 5件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Hematopoietic cell lineage, JAK-STAT signaling pathway, PI3K-Akt signaling pathway, Pathways in cancer 💬 | 1件: 49 49 |
528 | Growth Factors Laboratory Testing | - | - | - | - | 1件: 78 78 |
529 | Growth hormone | 1件: Somatotropin Somatotropin | 1件: D02691
D02691
| 1件: GHR GHR 💬 | 5件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Growth hormone synthesis, secretion and action, JAK-STAT signaling pathway, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway 💬 | 13件: 2 2, 13, 19, 46, 78, 96, 107, 187, 191, 193, 195, 265, 299 |
530 | Growth hormone (Genotonorm® or Omnitrope®) | 1件: Somatotropin Somatotropin | 1件: D02691
D02691
| 1件: GHR GHR 💬 | 5件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Growth hormone synthesis, secretion and action, JAK-STAT signaling pathway, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway 💬 | 2件: 78 78, 193 |
531 | Growth hormone (Genotropin) | 1件: Somatotropin Somatotropin | 1件: D02691
D02691
| 1件: GHR GHR 💬 | 5件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Growth hormone synthesis, secretion and action, JAK-STAT signaling pathway, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway 💬 | 1件: 78 78 |
532 | Growth hormone (Nutropin) | 1件: Somatotropin Somatotropin | 1件: D02691
D02691
| 1件: GHR GHR 💬 | 5件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Growth hormone synthesis, secretion and action, JAK-STAT signaling pathway, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway 💬 | 1件: 78 78 |
533 | Growth Hormone (Somatropin) | 1件: Somatotropin Somatotropin | 1件: D02691
D02691
| 1件: GHR GHR 💬 | 5件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Growth hormone synthesis, secretion and action, JAK-STAT signaling pathway, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway 💬 | 2件: 2 2, 78 |
534 | Growth hormone - LB03002 | 1件: Somatotropin Somatotropin | 1件: D02691
D02691
| 1件: GHR GHR 💬 | 5件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Growth hormone synthesis, secretion and action, JAK-STAT signaling pathway, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway 💬 | 1件: 78 78 |
535 | Growth hormone administration for 6 months | 1件: Somatotropin Somatotropin | 1件: D02691
D02691
| 1件: GHR GHR 💬 | 5件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Growth hormone synthesis, secretion and action, JAK-STAT signaling pathway, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway 💬 | 1件: 78 78 |
536 | Growth Hormone Releasing Hormone | 1件: Somatotropin Somatotropin | 1件: D02691
D02691
| 1件: GHR GHR 💬 | 5件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Growth hormone synthesis, secretion and action, JAK-STAT signaling pathway, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway 💬 | 1件: 265 265 |
537 | Growth hormone releasing hormone (GHRH) 1-44 | 2件: Somatorelin Somatorelin, Somatotropin | 2件: D02691
D02691
,
D08523
| 2件: GHR GHR, GHRHR 💬 | 5件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Growth hormone synthesis, secretion and action, JAK-STAT signaling pathway, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway 💬 | 1件: 78 78 |
538 | Growth hormone releasing hormone (GHRH) and arginine | 3件: Arginine Arginine, Somatorelin, Somatotropin | 3件: D02691
D02691
,
D02982
,
D08523
| 2件: GHR GHR, GHRHR 💬 | 5件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Growth hormone synthesis, secretion and action, JAK-STAT signaling pathway, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway 💬 | 1件: 78 78 |
539 | Growth Hormone Replacement Therapy | 1件: Somatotropin Somatotropin | 1件: D02691
D02691
| 1件: GHR GHR 💬 | 5件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Growth hormone synthesis, secretion and action, JAK-STAT signaling pathway, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway 💬 | 1件: 78 78 |
540 | Growth hormone replacement therapy in growth hormone deficient patients only. | 1件: Somatotropin Somatotropin | 1件: D02691
D02691
| 1件: GHR GHR 💬 | 5件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Growth hormone synthesis, secretion and action, JAK-STAT signaling pathway, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway 💬 | 1件: 78 78 |
541 | Growth Hormone Stimulation Test | 1件: Somatotropin Somatotropin | 1件: D02691
D02691
| 1件: GHR GHR 💬 | 5件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Growth hormone synthesis, secretion and action, JAK-STAT signaling pathway, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway 💬 | 1件: 299 299 |
542 | Growth Hormone, GH | 1件: Somatotropin Somatotropin | 1件: D02691
D02691
| 1件: GHR GHR 💬 | 5件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Growth hormone synthesis, secretion and action, JAK-STAT signaling pathway, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway 💬 | 1件: 78 78 |
543 | Growth Hormone-Releasing Hormone | 1件: Somatotropin Somatotropin | 1件: D02691
D02691
| 1件: GHR GHR 💬 | 5件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Growth hormone synthesis, secretion and action, JAK-STAT signaling pathway, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway 💬 | 1件: 78 78 |
544 | GS-248 | - | - | - | - | 1件: 51 51 |
545 | GS-4059 | - | - | - | - | 1件: 53 53 |
546 | GS-4875 | - | - | - | - | 1件: 97 97 |
547 | GS-4997 18 mg | - | - | - | - | 1件: 86 86 |
548 | GS-4997 2 mg | - | - | - | - | 1件: 86 86 |
549 | GS-4997 6 mg | - | - | - | - | 1件: 86 86 |
550 | GS-5737 | - | - | - | - | 1件: 299 299 |
551 | GS-5745 | 1件: GS-5745 GS-5745 | - | - | - | 4件: 46 46, 96, 97, 299 |
552 | GS-5745 IV | 1件: GS-5745 GS-5745 | - | - | - | 1件: 97 97 |
553 | GS-5745 SC | 1件: GS-5745 GS-5745 | - | - | - | 1件: 97 97 |
554 | GS-6034 | - | - | - | - | 4件: 46 46, 53, 96, 97 |
555 | GS-6615 3 mg | - | - | - | - | 1件: 58 58 |
556 | GS-6615 3 mg Pink | - | - | - | - | 1件: 58 58 |
557 | GS-6615 3 mg White | - | - | - | - | 1件: 58 58 |
558 | GS-6615 6 mg | - | - | - | - | 1件: 58 58 |
559 | GS-6615 6 mg White | - | - | - | - | 1件: 58 58 |
560 | GS-6624 | 1件: Simtuzumab Simtuzumab | - | - | - | 2件: 85 85, 94 |
561 | GS-9411 | - | - | - | - | 1件: 299 299 |
562 | GS-9674 | - | - | - | - | 2件: 93 93, 94 |
563 | GS-9674 100 mg | - | - | - | - | 1件: 93 93 |
564 | GS-9674 30 mg | - | - | - | - | 1件: 93 93 |
565 | GS-9876 | - | - | - | - | 2件: 46 46, 53 |
566 | GS010 | - | - | - | - | 1件: 302 302 |
567 | GS030-DP | - | - | - | - | 1件: 90 90 |
568 | GSH | - | - | - | - | 2件: 6 6, 299 |
569 | GSH (Glutathione) | 1件: Glutathione Glutathione | 2件: D00014
D00014
,
D00031
| - | - | 1件: 299 299 |
570 | GSK 3196165 | - | - | - | - | 1件: 46 46 |
571 | GSK1070806 | - | - | - | - | 2件: 56 56, 96 |
572 | GSK1223249 | - | - | - | - | 2件: 2 2, 13 |
573 | GSK1265744B (sodium salt) containing 14C-GSK1265744B | - | - | - | - | 1件: 265 265 |
574 | GSK1325760 | - | - | - | - | 2件: 86 86, 88 |
575 | GSK1325760A | - | - | - | - | 1件: 86 86 |
576 | GSK1399686 | - | - | - | - | 1件: 97 97 |
577 | GSK1550188 | - | - | - | - | 4件: 11 11, 49, 66, 222 |
578 | GSK1550188 (Belimumab) | 1件: Belimumab Belimumab | 1件: D03068
D03068
| 1件: TNFSF13B TNFSF13B 💬 | 4件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Intestinal immune network for IgA production, NF-kappa B signaling pathway, Rheumatoid arthritis 💬 | 1件: 222 222 |
579 | GSK1550188 1mg/kg or 10mg/kg | - | - | - | - | 1件: 49 49 |
580 | GSK1550188 IV | - | - | - | - | 1件: 49 49 |
581 | GSK1550188 SC | - | - | - | - | 1件: 49 49 |
582 | GSK1605786 | - | - | - | - | 2件: 96 96, 97 |
583 | GSK1605786 500 mg | - | - | - | - | 1件: 96 96 |
584 | GSK1605786 capsule | - | - | - | - | 1件: 96 96 |
585 | GSK1605786 ChemoCentryx: formulation A | - | - | - | - | 1件: 96 96 |
586 | GSK1605786 GSK direct-fill: formulation C | - | - | - | - | 1件: 96 96 |
587 | GSK1605786 GSK modified-process: formulation D | - | - | - | - | 1件: 96 96 |
588 | GSK1605786 GSK tablet: formulation E | - | - | - | - | 1件: 96 96 |
589 | GSK1605786 GSK: formulation B | - | - | - | - | 1件: 96 96 |
590 | GSK1605786A | - | - | - | - | 2件: 96 96, 97 |
591 | GSK1827771 | - | - | - | - | 1件: 46 46 |
592 | GSK1841157 | - | - | - | - | 3件: 13 13, 35, 46 |
593 | GSK2018682 | - | - | - | - | 1件: 13 13 |
594 | GSK2018682 CD2 Capsule | - | - | - | - | 1件: 13 13 |
595 | GSK2018682 CD3 micronised Tablet | - | - | - | - | 1件: 13 13 |
596 | GSK2018682 CD3 non-micronised Tablet | - | - | - | - | 1件: 13 13 |
597 | GSK2018682 CD3 non-micronised Tablet in fed state | - | - | - | - | 1件: 13 13 |
598 | GSK2126458 | - | - | - | - | 1件: 85 85 |
599 | GSK2256098 | 1件: GSK2256098 GSK2256098 | - | - | - | 1件: 86 86 |
600 | GSK2315698 | - | - | - | - | 1件: 28 28 |
601 | GSK2330672 | - | - | - | - | 1件: 93 93 |
602 | GSK2330811 | - | - | - | - | 2件: 51 51, 96 |
603 | GSK2330811 Solution for Injection, 100mg/ml | - | - | - | - | 1件: 51 51 |
604 | GSK239512 | - | - | - | - | 1件: 13 13 |
605 | GSK2395612 | - | - | - | - | 1件: 13 13 |
606 | GSK2398852 | - | - | - | - | 1件: 28 28 |
607 | GSK2402968 | - | - | - | - | 1件: 113 113 |
608 | GSK2402968 3mg/kg/week | - | - | - | - | 1件: 113 113 |
609 | GSK2402968 6 mg/kg/week | - | - | - | - | 1件: 113 113 |
610 | GSK2402968 6mg/kg/week | - | - | - | - | 1件: 113 113 |
611 | GSK2586184 | - | - | - | - | 1件: 49 49 |
612 | GSK2586184 100 mg | - | - | - | - | 1件: 49 49 |
613 | GSK2586184 200 mg | - | - | - | - | 1件: 49 49 |
614 | GSK2586184 400 mg | - | - | - | - | 1件: 49 49 |
615 | GSK2586184 400mg | - | - | - | - | 1件: 97 97 |
616 | GSK2586184 50 mg | - | - | - | - | 1件: 49 49 |
617 | GSK2586184 800mg single and repeat dose | - | - | - | - | 1件: 49 49 |
618 | GSK2586184 new formulation | - | - | - | - | 1件: 49 49 |
619 | GSK2586184 standard formulation | - | - | - | - | 1件: 49 49 |
620 | GSK2586881 | - | - | - | - | 1件: 86 86 |
621 | GSK2618960 | - | - | - | - | 1件: 53 53 |
622 | GSK2618960 2 mg/kg | - | - | - | - | 1件: 53 53 |
623 | GSK2788723 | - | - | - | - | 1件: 19 19 |
624 | GSK2831781 | - | - | - | - | 1件: 97 97 |
625 | GSK2831781 - Double Blind Phase | - | - | - | - | 1件: 97 97 |
626 | GSK2831781 - Open Label phase | - | - | - | - | 1件: 97 97 |
627 | GSK2857916 | - | - | - | - | 1件: 28 28 |
628 | GSK2973327 | - | - | - | - | 1件: 41 41 |
629 | GSK2982772 | - | - | - | - | 2件: 46 46, 97 |
630 | GSK2982772 60 mg | - | - | - | - | 1件: 46 46 |
631 | GSK2982772A, where A denotes the free base | - | - | - | - | 2件: 46 46, 97 |
632 | GSK3008348 | - | - | - | - | 1件: 85 85 |
633 | GSK3008348 Nebuliser solution | - | - | - | - | 1件: 85 85 |
634 | GSK3039294 | - | - | - | - | 1件: 28 28 |
635 | GSK3117391 | 1件: GSK-3117391 GSK-3117391 | - | - | - | 1件: 46 46 |
636 | GSK3152314A | - | - | - | - | 1件: 46 46 |
637 | GSK315234 | - | - | - | - | 1件: 46 46 |
638 | GSK315234 Injection 100mg/mL | - | - | - | - | 1件: 46 46 |
639 | GSK3196165 | - | - | - | - | 1件: 46 46 |
640 | GSK3196165 (Otilimab) | 1件: Otilimab Otilimab | 1件: D11343
D11343
| 1件: CSF2 CSF2 💬 | 16件: Acute myeloid leukemia Acute myeloid leukemia, Amoebiasis, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Fc epsilon RI signaling pathway, Hematopoietic cell lineage, Human T-cell leukemia virus 1 infection, IL-17 signaling pathway, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Natural killer cell mediated cytotoxicity, Rheumatoid arthritis, Shigellosis, T cell receptor signaling pathway, TNF signaling pathway, Transcriptional misregulation in cancer 💬 | 2件: 46 46, 256 |
641 | GSK3196165 Dose 1 | - | - | - | - | 1件: 46 46 |
642 | GSK3196165 Dose 2 | - | - | - | - | 1件: 46 46 |
643 | GSK3196165 Dose 3 | - | - | - | - | 1件: 46 46 |
644 | GSK356278 | - | - | - | - | 1件: 8 8 |
645 | GSK3888130B | - | - | - | - | 1件: 13 13 |
646 | GSK706769 | - | - | - | - | 1件: 46 46 |
647 | GSK962040 | - | - | - | - | 1件: 6 6 |
648 | GSK962040 (25 mg tablet) | - | - | - | - | 1件: 6 6 |
649 | GT4P | 1件: Glycerol phenylbutyrate Glycerol phenylbutyrate | 1件: D10127
D10127
| - | - | 1件: 251 251 |
650 | GTA (Glyceryl triacetate) | 1件: Triacetin Triacetin | 1件: D00384
D00384
| - | - | 1件: 307 307 |
651 | GTA glyceryl triacetate | 1件: Triacetin Triacetin | 1件: D00384
D00384
| - | - | 1件: 307 307 |
652 | GTA: Glyceryltriacetate | - | - | - | - | 1件: 307 307 |
653 | GTG003.08 | - | - | - | - | 1件: 65 65 |
654 | GTR | - | - | - | - | 1件: 13 13 |
655 | GTR.ace | - | - | - | - | 1件: 13 13 |
656 | GTX-102 | - | - | - | - | 1件: 201 201 |
657 | Guaiazulene | 1件: Guaiazulen Guaiazulen | - | - | - | 1件: 97 97 |
658 | GUANA2015 | - | - | - | - | 1件: 2 2 |
659 | GUANABENZ | 1件: Guanabenz Guanabenz | 1件: D04375
D04375
| 3件: ADRA2A ADRA2A, ADRA2B, ADRA2C 💬 | 2件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, cGMP-PKG signaling pathway 💬 | 2件: 2 2, 13 |
660 | GUANABENZ ACETATO | 1件: Guanabenz Guanabenz | 1件: D04375
D04375
| 3件: ADRA2A ADRA2A, ADRA2B, ADRA2C 💬 | 2件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, cGMP-PKG signaling pathway 💬 | 1件: 2 2 |
661 | Guanfacine | 1件: Guanfacine Guanfacine | 2件: D00606
D00606
,
D08031
| 1件: ADRA2A ADRA2A 💬 | 2件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, cGMP-PKG signaling pathway 💬 | 1件: 193 193 |
662 | Guanfacine extended release (GXR) | 1件: Guanfacine Guanfacine | 2件: D00606
D00606
,
D08031
| 1件: ADRA2A ADRA2A 💬 | 2件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, cGMP-PKG signaling pathway 💬 | 1件: 193 193 |
663 | Guanidine | 1件: Guanidine Guanidine | 1件: D02437
D02437
| - | - | 1件: 113 113 |
664 | Guar gum | 1件: Guar gum Guar gum | 1件: D04403
D04403
| - | - | 1件: 6 6 |
665 | Gum Arabic | 1件: Acacia Acacia | 1件: D02779
D02779
| - | - | 1件: 46 46 |
666 | Guna-Anti Interleukin 1 | - | - | - | - | 1件: 46 46 |
667 | Guna-Antiinterleukin 1 alfa | - | - | - | - | 1件: 46 46 |
668 | Guna-Antiinterleukin 1 beta | - | - | - | - | 1件: 46 46 |
669 | Guna-Interleukin 10 | - | - | - | - | 1件: 46 46 |
670 | Guna-Interleukin 4 | 1件: Binetrakin Binetrakin | 1件: D03117
D03117
| 1件: IL4 IL4 💬 | 16件: Allograft rejection Allograft rejection, Asthma, Autoimmune thyroid disease, Cytokine-cytokine receptor interaction, Fc epsilon RI signaling pathway, Hematopoietic cell lineage, IL-17 signaling pathway, Inflammatory bowel disease, Intestinal immune network for IgA production, JAK-STAT signaling pathway, Leishmaniasis, PI3K-Akt signaling pathway, Pathways in cancer, T cell receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation 💬 | 1件: 46 46 |
671 | Guselkum | - | - | - | - | 1件: 97 97 |
672 | GUSELKUMAB | 1件: Guselkumab Guselkumab | 1件: D10438
D10438
| 1件: IL23A IL23A 💬 | 9件: C-type lectin receptor signaling pathway C-type lectin receptor signaling pathway, Cytokine-cytokine receptor interaction, Inflammatory bowel disease, JAK-STAT signaling pathway, Pathways in cancer, Pertussis, Rheumatoid arthritis, Th17 cell differentiation, Tuberculosis 💬 | 5件: 37 37, 41, 51, 96, 97 |
673 | Guselkumab 100 mg | 1件: Guselkumab Guselkumab | 1件: D10438
D10438
| 1件: IL23A IL23A 💬 | 9件: C-type lectin receptor signaling pathway C-type lectin receptor signaling pathway, Cytokine-cytokine receptor interaction, Inflammatory bowel disease, JAK-STAT signaling pathway, Pathways in cancer, Pertussis, Rheumatoid arthritis, Th17 cell differentiation, Tuberculosis 💬 | 1件: 37 37 |
674 | Guselkumab Dose 1 | 1件: Guselkumab Guselkumab | 1件: D10438
D10438
| 1件: IL23A IL23A 💬 | 9件: C-type lectin receptor signaling pathway C-type lectin receptor signaling pathway, Cytokine-cytokine receptor interaction, Inflammatory bowel disease, JAK-STAT signaling pathway, Pathways in cancer, Pertussis, Rheumatoid arthritis, Th17 cell differentiation, Tuberculosis 💬 | 3件: 51 51, 96, 97 |
675 | Guselkumab Dose 2 | 1件: Guselkumab Guselkumab | 1件: D10438
D10438
| 1件: IL23A IL23A 💬 | 9件: C-type lectin receptor signaling pathway C-type lectin receptor signaling pathway, Cytokine-cytokine receptor interaction, Inflammatory bowel disease, JAK-STAT signaling pathway, Pathways in cancer, Pertussis, Rheumatoid arthritis, Th17 cell differentiation, Tuberculosis 💬 | 3件: 51 51, 96, 97 |
676 | Guselkumab Dose 3 | 1件: Guselkumab Guselkumab | 1件: D10438
D10438
| 1件: IL23A IL23A 💬 | 9件: C-type lectin receptor signaling pathway C-type lectin receptor signaling pathway, Cytokine-cytokine receptor interaction, Inflammatory bowel disease, JAK-STAT signaling pathway, Pathways in cancer, Pertussis, Rheumatoid arthritis, Th17 cell differentiation, Tuberculosis 💬 | 1件: 96 96 |
677 | Guselkumab Dose 4 | 1件: Guselkumab Guselkumab | 1件: D10438
D10438
| 1件: IL23A IL23A 💬 | 9件: C-type lectin receptor signaling pathway C-type lectin receptor signaling pathway, Cytokine-cytokine receptor interaction, Inflammatory bowel disease, JAK-STAT signaling pathway, Pathways in cancer, Pertussis, Rheumatoid arthritis, Th17 cell differentiation, Tuberculosis 💬 | 1件: 96 96 |
678 | Guselkumab Dose 5 | 1件: Guselkumab Guselkumab | 1件: D10438
D10438
| 1件: IL23A IL23A 💬 | 9件: C-type lectin receptor signaling pathway C-type lectin receptor signaling pathway, Cytokine-cytokine receptor interaction, Inflammatory bowel disease, JAK-STAT signaling pathway, Pathways in cancer, Pertussis, Rheumatoid arthritis, Th17 cell differentiation, Tuberculosis 💬 | 1件: 96 96 |
679 | Gusperimus | 1件: Gusperimus Gusperimus | 1件: D08032
D08032
| - | - | 1件: 44 44 |
680 | Gusperimus + glucocorticoids | 1件: Gusperimus Gusperimus | 1件: D08032
D08032
| - | - | 1件: 44 44 |
681 | Gutron 2,5mg | - | - | - | - | 1件: 58 58 |
682 | Gutron 5mg | - | - | - | - | 1件: 58 58 |
683 | GVHD Prophylaxis | - | - | - | - | 2件: 60 60, 65 |
684 | GW-1000-02 | - | - | - | - | 1件: 13 13 |
685 | GW274150 | - | - | - | - | 1件: 46 46 |
686 | GW274150 Tablets | - | - | - | - | 1件: 46 46 |
687 | GW406381 | - | - | - | - | 1件: 46 46 |
688 | GW406381X | - | - | - | - | 1件: 46 46 |
689 | GW582892 | - | - | - | - | 1件: 144 144 |
690 | GW856553 | - | - | - | - | 1件: 46 46 |
691 | GWP42003 | - | - | - | - | 1件: 97 97 |
692 | GWP42003-P | - | - | - | - | 5件: 140 140, 144, 145, 156, 158 |
693 | GWP42003-P 10 mg/kg/day Dose | - | - | - | - | 1件: 140 140 |
694 | GWP42003-P 20 mg/kg/day Dose | - | - | - | - | 2件: 140 140, 144 |
695 | GWP42003-P 5 mg/kg/day Dose | - | - | - | - | 1件: 140 140 |
696 | GX 623 | - | - | - | - | 1件: 135 135 |
697 | GX CJ7 | - | - | - | - | 1件: 135 135 |
698 | GX-H9 | - | - | - | - | 1件: 78 78 |
699 | GYLENIA | - | - | - | - | 1件: 13 13 |
700 | GYLENIA 0,5 mg | - | - | - | - | 1件: 13 13 |
701 | GYM329 | - | - | - | - | 1件: 3 3 |
702 | GYPP-06 (GKT137831 free base), C10071301-D | - | - | - | - | 1件: 93 93 |
703 | GZ/SAR402671 | - | - | - | - | 2件: 19 19, 67 |
704 | GZ385660 | - | - | - | - | 1件: 19 19 |
705 | GZ402665 | - | - | - | - | 1件: 19 19 |
706 | GZ402666 | - | - | - | - | 1件: 256 256 |
707 | GZ402668 | - | - | - | - | 1件: 13 13 |
708 | GZ402669 | - | - | - | - | 1件: 222 222 |
709 | GZ402671 | - | - | - | - | 2件: 19 19, 67 |
710 | GZ402671 / SAR402671 | - | - | - | - | 1件: 19 19 |
711 | GZ402673 | - | - | - | - | 1件: 13 13 |
712 | GZ419829 | - | - | - | - | 1件: 256 256 |